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Staphylococcus aureus is one of the most common pathogens that cause a wide 
range of infections ranging from skin and soft tissue infections to invasive, life-
threatening infections. The emergence of methicillin-resistant Staphylococcus aureus 
(MRSA) substantially increased healthcare burdens associated with Staphylococcal 
infections because of high morbidity and mortality and increasing the need for efficient 
and cost-effective screening methods, for high-risk patients. The objective of this study 
is to develop two molecular methods, real-time PCR and loop-mediated isothermal 
amplification (LAMP), and validate them following Clinical Laboratory Improvement 
Amendments (CLIA) and College of American Pathologists (CAP) standards. The real-
time PCR assay was developed targeting mecA, mecC, nuc, and coa to detect S. aureus 
and methicillin-resistance. The assay had high precision, a linear range of 104-108 
CFU/ml, and 95% accuracy. The assay detects MRSA, MSSA, MR-CoNS, and MS-
CoNS. The LAMP assay was developed targeting the same genes; however, its lower 
limit of detection was 106 CFU/ml, which was much higher than that of the real-time 
PCR assay. Additional studies are required to optimize the performance characteristics 
of the LAMP assay further. Nevertheless, the real-time PCR assay developed in this 










This work is dedicated to my mother, who showed me the value of hard work and 
education.  







 I would first like to thank my thesis Advisor Dr. Marawan Abu Madi, of the 
College of Health Sciences at Qatar University and the Thesis Committee members for 
their support and guidance throughout the process of conducting the experiment and 
writing the thesis. 
 I would also like to thank Drs. Patrick Tang, Mohammad Rubayet Hasan, and 
Nahla Omer Eltai for their guidance and help and allowing me the time and opportunity 
to see this project to completion. 
 Special thanks go to the Microbiology team at Sidra Medicine, in particular, 
Nazik Elamin and Sarah Dumindin, for their help in collecting the clinical specimens 
and other materials that I needed for my experiments. Without their eagerness to help, 
this project would not have succeeded. 
 I must also express my very profound gratitude to my parents, family, and my 
friend and brother Djamshid Mulla-Akhunov for providing me unfailing support and 
continuous encouragement throughout my studies the research and writing processes. 
The road was rough, and I would not have pulled through without them. 
 Finally, I must express my thanks to the Department of Pathology at Sidra 







TABLE OF CONTENTS 
DEDICATION .............................................................................................................. iv 
ACKNOWLEDGMENTS ............................................................................................. v 
LIST OF TABLES ......................................................................................................... x 
LIST OF FIGURES ...................................................................................................... xi 
Chapter 1: Introduction .................................................................................................. 1 
The Clinical Significance of Staphylococcus aureus ................................................. 1 
Methicillin-Resistant S. aureus (MRSA) ................................................................... 1 
MRSA Surveillance.................................................................................................... 2 
Methicillin-Resistance and its Detection.................................................................... 4 
Polymerase Chain Reaction (PCR) ............................................................................ 7 
Loop-Mediated Isothermal Amplification (LAMP) ................................................. 11 
LAMP Primer Design............................................................................................... 15 
Objectives ................................................................................................................. 16 
Chapter 2: Literature Review ....................................................................................... 19 
MRSA Detection by PCR ........................................................................................ 19 
MRSA Detection by LAMP ..................................................................................... 21 
Chapter 3: Methods ...................................................................................................... 26 
Real-time PCR primers and probes .......................................................................... 26 




Primer and probe assessment ................................................................................ 26 
LAMP primers.......................................................................................................... 31 
Primer design ........................................................................................................ 31 
Primer set assessment ........................................................................................... 31 
Positive controls ....................................................................................................... 37 
Real-time PCR assay optimization ........................................................................... 41 
Primer/probe initial verification ........................................................................... 41 
Optimization ......................................................................................................... 42 
Final verification................................................................................................... 43 
LAMP assay optimization ........................................................................................ 43 
Primer/probe initial verification ........................................................................... 43 
LAMP Optimization ............................................................................................. 44 
Clinical specimens.................................................................................................... 45 
DNA extraction ........................................................................................................ 45 
Assay validation ....................................................................................................... 46 
Statistical analysis .................................................................................................... 47 
Ethical compliance ................................................................................................... 48 
Chapter 4: Results ........................................................................................................ 49 
Real-time PCR assay Verification and Optimization ............................................... 49 




LAMP Assay Verification and Optimization ........................................................... 54 
Chapter 5: Discussion .................................................................................................. 57 
Designing a Molecular Assay .................................................................................. 57 
Real-Time PCR ........................................................................................................ 59 
Clinical Validation ................................................................................................ 59 
LAMP ....................................................................................................................... 61 
Chapter 6: Conclusion.................................................................................................. 63 
References .................................................................................................................... 65 
APPENDIX A: Target Gene Reference Sequences ..................................................... 71 
APPENDIX B: In silico Specificity Reference Sequences.......................................... 76 
APPENDIX C: Novel Real-Time PCR coa Primer/Probe Sequence Alignment for In 
Silico Specificity .......................................................................................................... 79 
APPENDIX D: Novel Real-Time PCR mecA Primer/Probe Sequence Alignment for In 
Silico Specificity .......................................................................................................... 82 
APPENDIX E: Novel Real-Time PCR mecC Primer/Probe Sequence Alignment for In 
Silico Specificity .......................................................................................................... 84 
APPENDIX F: Novel Real-Time PCR nuc Primer/Probe Sequence Alignment for In 
Silico Specificity .......................................................................................................... 87 
APPENDIX G: Real-Time PCR LOD Results ............................................................ 90 
APPENDIX H: Real-Time PCR Clinical Validation Results ...................................... 94 









LIST OF TABLES 
Table 1. LAMP Literature Review Summary .............................................................. 23 
Table 2. Real-time PCR Primers and Probes ............................................................... 28 
Table 3. LAMP Primers ............................................................................................... 32 
Table 4. Positive Control Quantification for mecA, nuc, and coa ............................... 39 
Table 5. mecC Plasmid Dilutions and Quantification .................................................. 40 
Table 6. LAMP Positive Control Quantification (mecA, coa, and nuc) ...................... 41 
Table 7. LAMP Optimization Matrix .......................................................................... 44 
Table 8. List of Organisms in the Specificity Panel .................................................... 47 
Table 9. Multiplex Real-Time PCR: TaqMan vs. TaqPath ......................................... 50 
Table 10. Singleplex vs. Multiplex Real-Time PCR with TaqPath. ............................ 51 





LIST OF FIGURES 
Figure 1. PCR reaction schematic .................................................................................. 8 
Figure 2. PCR Product Gel Electrophoresis .................................................................. 9 
Figure 3. TaqMan Probe .............................................................................................. 11 
Figure 4. LAMP target DNA structure ........................................................................ 12 
Figure 5. LAMP mechanism outline ............................................................................ 14 
Figure 6. Primer design work-flow. ............................................................................. 30 
Figure 7. Positive control plates for mecA, nuc, and coa. ............................................ 38 
Figure 8. Real-time PCR linearity plots ....................................................................... 53 
Figure 9. Melt curve plot for mecA1 LAMP primer set with ATCC 976 ................... 55 





Chapter 1: Introduction 
The Clinical Significance of Staphylococcus aureus 
 Staphylococcus aureus is a gram-positive bacterial species that is a common 
part of the normal human flora. It is a commensal colonizer of the axillae, nares, 
pharynx, vagina, rectum, perineum and damaged skin [1, 2]. Depending on bacterial 
virulence and host factors, this colonization may turn into an infection and cause 
various complications, including skin and soft tissue infections (SSTIs), pneumonia, 
surgical site and medical implant infections, and bacteremia. S. aureus is the most 
commonly isolated pathogen in SSTIs, accounting for up to 50% of isolates [3]. It is 
increasingly problematic in neonatal intensive care units (NICUs) worldwide, due to 
the vulnerability of preterm and critically ill neonates and the ability of S. aureus to 
survive on environmental surfaces for long periods [4]. Another particularly vulnerable 
subset of patients is those with cystic fibrosis (CF). S. aureus is the third most prevalent 
bacterial isolate in CF patients in the United States of America (USA) and is increasing 
in other countries [5]. The emergence of antimicrobial resistance (AMR), particularly 
methicillin-resistant S. aureus (MRSA), has magnified the health care burden 
associated with S. aureus infections. MRSA was found to result in substantially higher 
morbidity and mortality than methicillin-sensitive S. aureus (MSSA) and increased 
health care costs [6-8]. 
 
Methicillin-Resistant S. aureus (MRSA) 
 MRSA was first isolated shortly after the introduction of the antibiotic 
methicillin in 1961 in the United Kingdom (UK) [9-12]. A few years later, more isolates 
were identified in Canada and followed by an outbreak a little more than a decade after 
their initial emergence [12]. Up until the mid-1980s, MRSA was a healthcare-acquired 




cases of young patients, with no history of hospitalization, with MRSA infections 
started appearing in indigenous communities in Canada and Australia [11]. Therefore, 
MRSA isolates have been classified as either hospital-acquired (HA-MRSA) or 
community-acquired (CA-MRSA). The two types can differ in their AMR patterns and 
genotypes. For example, methicillin resistance in HA-MRSA and CA-MRSA develops 
through different mobile genetic elements [13-15]. However, as MRSA strains have 
become more widespread in the community, the distinction between HA-MRSA and 
CA-MRSA has become less useful. 
 Nasal and skin MRSA colonization are a significant risk factor for SSTIs both 
in the hospitals and in the community [3]. The health care burden of MRSA has been 
progressively increasing in the past years, leading to increases in morbidity, mortality, 
and health care costs [3]. By 2005, mortality from MRSA in the US exceeded that of 
Salmonella, tuberculosis, influenza, and HIV combined [16, 17]. Proper identification 
and control measures for MRSA must be implemented to prevent increases in carriage 
and infection rates, as is the case with northern Saskatchewan, Canada, where the 
incidence of CA-MRSA increased from 8.2 cases per 10,000 in 2001 to 168.1 per 
10,000 in 2006 [18]. In 2015, MRSA accounted for 20-30% of SSTIs in Europe and 
Latin America and up to 35% in North America [3]. Significant efforts have been made 
in the reduction of mortality due to MRSA, with much of this effort driven by the early 
identification of carriers of MRSA to prevent its spread in health care settings and 
rapidly identify S. aureus isolates that are MRSA.  
 
MRSA Surveillance  
 Successful efforts in the prevention of MRSA and subsequent reduction in 
mortality focused on active surveillance programs (ASP) [19]. Most MRSA carriers are 




estimated that, in the absence of ASP, routine cultures only identify 18% of MRSA 
carriers [20]. These individuals, while asymptomatic, can develop infections later or 
spread MRSA to others. It is estimated that 25% of carriers in intensive care units 
(ICUs) develop MRSA infections [20]. Thus, ASPs are necessary to prevent and control 
MRSA spread. ASPs may include screening all patients for MRSA during general 
admission at the hospital or screening specific risk groups. Patient risk groups include 
pre-operative, immunosuppressed, ICU and NICU patients [3]. Contact precautions are 
used for health care providers and visitors to patients who may carry MRSA to prevent 
the spread of the organism in hospital settings. In some situations, the successful 
decolonization of patients with MRSA may reduce the chance of MRSA infections. A 
clinical trial investigating the impact of S. aureus surveillance and pre-operative 
decolonization with joint replacement surgeries found that decolonization of pre-
operative patients reduced surgical site infections by 50% [21]. 
 Furthermore, a prospective, controlled, interventional cohort-study of 33 
surgical wards in 10 hospitals across Europe and Israel demonstrated that active 
surveillance, contact precautions, and decolonization are significantly associated with 
reduced risk of MRSA infections [22]. However, decolonization of patients remains a 
controversial issue. Despite stringent decolonization measures, patients can remain 
positive or become re-colonized upon readmission to the hospital [23]. In other cases, 
poor sample collection techniques can produce false-negative results. Successful ASPs 
depend on the methods used to screen for MRSA. These range from various culture 
methods to molecular methods. When choosing a screening method, the laboratory 
must consider sensitivity, specificity, turn-around time, labor and cost. 
 Screening for MRSA is usually performed on swabs from nares or a 




When testing one site only, the nares swabs are typically used as they are the most 
common site of colonization. However, testing nares swabs alone can miss up to 35% 
of patients colonized with MRSA [19]. In the past, the swabs were cultured on non-
selective media (blood agar and chocolate agar) or selective media (mannitol salt agar). 
More recently, chromogenic agar and molecular testing have become more widely 
available [24, 25]. Most laboratories choose between chromogenic media and real-time 
polymerase chain reaction (PCR), as both can produce results within 24 hours [26]. 
Chromogenic media has a sensitivity of about 80% at 25 hours, and it must be incubated 
longer, up to 48 hours, for the sensitivity to approach 100% [26]. As for molecular 
assays, the first commercial assay for S. aureus was the “Gen-Probe Accuprobe 
Staphylococcus aureus Culture Identification Test” for positive blood cultures in the 
1990s [27]. The assay uses a chemiluminescent DNA probe for the S. aureus-specific 
16S rRNA gene and provides results in less than an hour, but the assay is designed for 
use on clinical isolates and not on clinical specimen [27, 28]. Later, molecular testing 
moved towards commercial and in-house developed PCR assays targeting genes unique 
to S. aureus, such as femA, nuc or spa [29]. The further differentiation of MSSA from 
MRSA is possible by incorporating primers and probes for the mecA gene, which codes 
for the methicillin resistance [30]. Some coagulase-negative staphylococcal (CoNS) 
species also carry the mecA gene, so mecA PCR must be performed only on confirmed 
S. aureus isolates or in conjunction with PCR targeting S. aureus-specific genes. 
 
Methicillin-Resistance and its Detection 
 The mecA gene codes for a penicillin-binding protein (PBP2a) homolog that has 
less affinity to β-lactam antibiotics [5, 31]. β-lactams work by binding the penicillin-
binding proteins and inhibiting peptidoglycan cross-linking, resulting in cell lysis. The 




its affinity to -lactam antibiotics [32]. MRSA evolved from MSSA after it acquired 
the SCCmec element, a 21-67kbp mobile staphylococcal genetic element that carries 
the mecA gene, site-specific recombinase genes (ccr complexes) and a joining region 
[31, 33]. SCCmec is located near the origin of replication of the staphylococcal 
chromosome (orfX) [31]. The position of SCCmec relative to orfX provides a specific 
target site for PCR amplification for MRSA. Eleven types of SCCmec have been 
identified in staphylococcal species, differing in the mec gene and ccr complexes [31] 
The SCC types I, II and III give methicillin resistance in HA-MRSA, while CA-MRSA 
gains its resistance through SCCmec types IV and V [34]. The SCCmec types in HA-
MRSA are generally larger than CA-MRSA and confer resistance to more antibiotics. 
HA-MRSA, for instance, is resistant to clindamycin, while CA-MRSA is susceptible 
[34]. The varying resistance profiles can be attributed to the ccr region, which may 
harbor multiple antibiotic resistance genes [31]. In 2007, a new variant of S. aureus was 
found in the UK, which was phenotypically determined to be MRSA, but confirmatory 
tests were negative for mecA [32]. Sequencing found that the gene conferring the 
resistance had only ~69% nucleotide identity to mecA, and the encoded PBP (PBP2c) 
was only ~63% identical at the amino acid level [32]. This new gene was termed mecC, 
and a new type of SCCmec was identified. Due to the low homology between mecA 
and mecC, molecular assays targeting mecA can miss many mecC MRSA. 
 The SCCmec element is not unique to MRSA and can be found in coagulase-
negative staphylococcal species. Molecular screening requires a robust method to 
specifically detect MRSA rather than detecting methicillin-resistance in other 
staphylococcal species. Also, patients can be colonized with multiple species of 
organisms. While the gold standard for MRSA identification is by culture, molecular 




and multiple commercial assays are available. A literature search of real-time PCR for 
MRSA also reveals a plethora of in-house developed assays. What these, as well as 
commercial assays, have in common is the algorithm used in interpreting the results of 
a multiplex PCR. The assays target a S. aureus-specific gene, and the mecA gene or a 
portion of SCCmec. Some newer assays also incorporate the mecC gene. Hirvonen 
(2014) reviewed multiple molecular methods for the detection and identification of 
MRSA. The review included a comparison of multiple nucleic acid-based tests, both 
in-house and commercial, and non-nucleic acid-based tests [35]. Hirvonen compared 
the assays in terms of sensitivity, specificity, and turn-around time and run-time. Turn-
around time is the time taken from specimen receipt to result reporting, while run-time 
is the time taken from starting the test to completion. Chromogenic agar had a turn-
around time of 16-48 hours, sensitivity ranging from 44.1-100%, and specificity of 
97.2-100%.  
 Other non-nucleic acid-based assays included latex agglutination, matrix-
assisted laser desorption/ionization-time of flight (MALDI-TOF), and biochemical 
identification and susceptibility testing by Vitek 2. The run-time for these assays ranged 
between 3 minutes to 12 hours. However, all of them require bacteriologic culture and 
organism isolation first, adding at least 16 hours to the total turn-around time [35]. For 
nucleic acid-based assays, Hirvonen compared multiple in-house and commercial real-
time PCR assays, including GeneOhm MRSA (Becton Dickson), Xpert MRSA and 
Xpert MRSA/SA (Cepheid Diagnostics), BD MAX MRSA (Becton Dickson), Light 
Cycler MRSA (Roche Diagnostics), in-house developed assays and a LAMP assay. The 
sensitivity from clinical specimens ranged from 69.2-100% and specificity from 64.5-
100%. The turn-around time ranged from 1 hour to 3 hours [35]. Even when including 




than non-nucleic acid-based assays. Particularly interesting is the LAMP assay (loop-
mediated isothermal amplification), which showed the shortest run-time (1 hour), high 
specificity (100%) and sensitivity ranging from 91.3-98.4%. When considering 
molecular assays, the biggest hurdle tends to be the cost. Real-time PCR instruments 
are expensive due to the complex components required for thermal cycling and 
fluorescence detection. LAMP, however, is isothermal, thus removing the need for such 
sophisticated machinery, requiring only the maintenance of constant temperature. 
LAMP was first described by Notomi et al. (2000) as a novel method for nucleic acid 
amplification. The method is capable of amplifying DNA from a few copies to 109 in 
less than an hour [36]. Unlike PCR, LAMP is performed under isothermal conditions 
and without requiring a thermal cycler. Furthermore, LAMP is more specific than other 
isothermal nucleic acid amplification methods, such as nucleic acid sequence-based 
amplification (NASBA) and self-sustained sequence replication (3SR), and does not 
require the use of expensive modified nucleotides as in strand displacement 
amplification (SDA). Furthermore, LAMP is not significantly affected by the presence 
of non-target DNA [36]. 
 
Polymerase Chain Reaction (PCR) 
 The Polymerase Chain Reaction (PCR) was developed by Kary Mullis in 1983 
and marked a significant milestone in the field of molecular biology [37]. PCR is a 
powerful technique that has become one of the most widely used techniques in 
molecular biology [38, 39].  
 The technique is based on the cellular DNA replication mechanism. In a PCR 
reaction, a DNA molecule is replicated, and each product is replicated again in another 
cycle, resulting in exponential amplification of the DNA molecule [39]. A typical PCR 




guanine, and cytosine), and primers [39]. 
 The reaction is dependent on thermal cycling, in which each cycle consists of 
three steps, denaturation, annealing, and extension, at varying temperatures. The 
double-stranded DNA is denatured at temperatures around 90-97°C separating it into 
single strands, each acting as a template for the following steps [39]. Then, the primers 
anneal to strands to prime extension at a lower temperature (50-60°C) to allow the 
primers to anneal. Finally, the temperature is increased to the optimum temperature for 
the polymerase for DNA synthesis to occur (Figure 1). These three steps constitute a 
cycle. The reaction can be performed for multiple cycles to increase the amount of 
product DNA [39]. The final products of the reaction can be analyzed by agarose gel 
electrophoresis, where the amplicons can be visualized as distinct bands of the expected 
size (Figure 2). 
 
 
Figure 1. PCR reaction schematic 






Figure 2. PCR Product Gel Electrophoresis 
(Source: Larsen et al. 2008 [40]). 
 
 During the extension step, the DNA polymerase binds to the annealed primer 
and synthesizes complementary DNA using the available dNTPs. The polymerase most 
commonly used in PCR reactions is Taq polymerase or one of its variants [39]. It is a 
thermostable DNA polymerase, isolated from Thermus aquaticus, that can withstand 
the high temperatures used in the PCR reaction [41]. Other polymerases have also been 
developed and vary in their properties to suit their intended applications [41]. When 
choosing a polymerase, some considerations are its specificity, thermostability, fidelity, 
and processivity. As with the type of polymerase used, there are other reagent 
considerations to be taken into account when performing a PCR reaction. Primers are 
designed to be specific to the region intended to be amplified, and thus their sequence 
must be complementary to the region but not to others. 
 Additionally, two primers must be designed, each complementary to one strand 
of the DNA. However, with the varying sequences of primers needed for different 




including the primer melting temperatures, GC-content, secondary structure formation, 
and dimerization. The tools and software to perform all these analyses in silico are 
widely available with both free-to-use and commercial options [42]. 
 Almost a decade after PCR was first described, the concept of monitoring 
amplification in real-time was introduced [43]. Real-time PCR follows the same 
principle as traditional PCR with the addition of fluorescent molecules to monitor the 
amplification reaction. In real-time PCR, detection can be done with two chemistries, 
DNA binding dyes or fluorophore-labeled oligonucleotides [44]. DNA binding dyes 
bind to double-stranded DNA, resulting in a complex that absorbs light and 
subsequently fluoresces [44]. The most commonly used DNA binding dye is SYBR® 
Green I [44]. Fluorophore-labeled oligonucleotides are segments of DNA bound to a 
fluorescent molecule. They can be divided into multiple groups based on their structures 
and mechanism of fluorescence; these are hairpin primer-probes, hydrolysis probes, and 
hybridization probes [44]. One such oligonucleotide is the so-called Taqman probe. 
Taqman probes are segments of DNA complementary to a region in the target DNA 
between the two primer binding sites and has a fluorophore and quencher on each end 
[45]. In solution, the intact probe does not fluoresce because the quencher absorbs the 
energy released from the fluorophore due to proximity. However, during the extension 
step, the 5-3 exonuclease activity of the DNA polymerase excises the probe and 
releases the quencher and fluorophore. The excision enables the fluorophore to emit a 
signal that can be detected (Figure 3). With both DNA binding dyes and fluorophore-
labeled oligonucleotides, the amount of fluorescence is proportional to the amount of 





Figure 3. TaqMan Probe 
(Source: Thermofischer Scientific Website). 
 
Loop-Mediated Isothermal Amplification (LAMP) 
 The LAMP method relies on auto-cycling strand displacement DNA synthesis. 
The reaction is performed using a DNA polymerase with high strand displacement 
activity aided by sets of two inner and two outer primers. Bst DNA polymerase, derived 
from Bacillus stearomophilus, is frequently used in LAMP reactions. The enzyme has 
optimum activity at 60-65°C and high concentrations of magnesium. It can be 
inactivated by incubating for 15 minutes at 80°C [41, 46]. LAMP primers are designed 
based on six regions within the target. Two 23-34 nucleotide long DNA sequences 
inside both ends of the target, designated F2c and B2; two 40 nucleotide long DNA 
sequences from the inner ends of F2c and B2, designated F1c and B1; and two 
sequences outside the ends of F2c and B2, designated F3c and B3 (Figure 4) [36]. The 




Primer (BIP) for the inner primers and F3 and B3 for the outer primers, are based on 
the designated sequences on the target. FIP contains the F1c sequence (complementary 
to F1), a polyT spacer, and the F2 sequence (complementary to F2c). Similarly, BIP 
contains B1, a polyT spacer, and B2c. The two outer primers contain the sequences F3 
and B3 for the forward and backward primers, respectively. A mixture of the target and 
four primers are heat denatured at 65°C and rapidly cooled on ice, then mixed with the 
DNA polymerase, and the reaction proceeds for 1 hour at 65°C [36]. 
 
 
Figure 4. LAMP target DNA structure 
(Source: Eiken Chemical Co. Ltd. website). 
 
 The LAMP reaction mechanism proceeds in three stages: 1) production of a 
stem-loop structure, 2) cycling amplification, 3) elongation, and recycling [36]. The 
reaction starts when FIP displaces the DNA strands, and the F2 sequence anneals to its 
complementary sequence. A DNA polymerase with high strand displacement activity 
then extends the primer while displacing the strands, starting with the 3 end of the F2 
segment. The result is a strand of DNA complementary to the target and linked to FIP. 
Then, the outer primer (F3) anneals to its complementary region, upstream of F2. 
Extension of this primer displaces the FIP-linked strand. The displaced FIP-linked 
strand forms a stem-loop structure due to the reverse complementarity of the F1c region 
and a region within the target. This stem-loop structure serves as a template for BIP and 




with a stem-loop at each end, formed by F1 and F1c on one side, and B1 and B1c on 
the other. This dumbbell-shaped structure serves as the base for the subsequent cycling 
amplification. The structure contains multiple sites for primer annealing and DNA 
synthesis. Amplification occurs through auto-cycling, resulting in continuous strand 





Figure 5. LAMP mechanism outline 






 In addition to F3, B3, FIP, and BIP, specific primers targeting the loop regions 
of the amplified products (Termed Loop Primers, LF, and LB) can result in a reduction 
of the time to amplification by half or two-thirds [48]. These loop primers correspond 
to two sequences within the target. The forward loop primer (LF) corresponds to the 
region between F1 and F2, and the backward loop primer (LB) corresponds to the 
region between B1 and B2. 
 
LAMP Primer Design 
 When designing LAMP primers, several factors need to be considered. First, 
the meting-temperature (Tm) of the F2 and B2 sequences in the FIP and BIP primers 
have to be within the optimal range of the polymerase [36]. The Tm for F1c and B1c 
(the other sequences of FIP and BIP) need to be slightly higher, however, so that the 
loop structure can form immediately after the denaturation of the target DNA. Finally, 
the Tm for F3 and B3 (the outer primers) needs to be lower than F2 and B2, to ensure 
that the inner primers (FIP and BIP) anneal and synthesis from them starts first [36]. 
 Another factor in LAMP primer design is the length of the FIP and BIP 
sequences as it affects the size of the stem-loop structure, the formation of which is 
essential for the amplification reaction. Notomi et al. (2000) experimented with 
multiple sizes and found a length of 40 bases or longer gave the best amplification 
efficiency [36]. Additionally, the distance between the F2 and B2 and between F2 and 
F3 should be 120-180bp and 0-20bp respectively. Furthermore, the stability of binding 
at the 3 end of the primer is essential for the reaction to proceed, as it is the starting 
point DNA synthesis. LAMP is an isothermal reaction that depends on auto-cycling. 
Thus, annealing of the primers must generate a negative change in free energy (ΔG) to 




[49]. Similarly, the GC content of the primer should be between 40-65% to ensure the 
stability of primer binding, and secondary structures should be minimized. 
 
Objectives 
 The overarching aim of this study is to develop a cost-effective method for the 
detection of MRSA from clinical samples for use in the Molecular Infectious Diseases 
Laboratory at Sidra Medicine. To that end, our goal is to develop and validate in-house 
real-time PCR and LAMP assays for the detection of MRSA from patient specimens 
with high sensitivity and specificity, short turn-around time, and low cost. The in-house 
developed LAMP assay will be compared to both culture-based testing and the in-house 
developed real-time PCR assay targeting the same genes. The sensitivity, specificity, 
accuracy, precision, robustness, specimen preparation time, assay run-time, and cost 
per specimen will be compared using clinical specimens sent to the microbiology 
laboratory for MRSA screening by culture (N= 200). The accuracy of the MRSA PCR 
results will be assessed based on the agreement with microbiology culture results. 
Successful completion of the project will result in two in-house developed, cost-
effective molecular assays for the rapid screening of MRSA. Ultimately, the better 
assay will be adopted as an alternative method for MRSA detection at the Molecular 
Infectious Diseases Laboratory of Sidra Medicine. The goal of the study will be 
achieved through the following specific objectives: 
 Specific objective 1: Develop an in-house real-time PCR assay for MRSA 
detection. 
o Sub-objective 1.1: design primers and probes targeting S. aureus and 
methicillin-resistance.  
o Sub-objective 1.2: Design plasmids for custom synthesis (commercial) 




assay conditions and c) to determine analytical performance 
characteristics of different PCR assays. 
o Sub-objective 1.3: optimize assay conditions (annealing temperature 
and reagent concentration). 
o Sub-objective 1.4: determine the performance characteristics of the 
assay (precision, analytical sensitivity, analytical specificity, and 
linearity).  
 
 Specific objective 2: Develop an in-house LAMP assay for MRSA detection. 
o Sub-objective 2.1: design primers for S. aureus and methicillin-
resistance. 
o Sub-objective 2.2: optimize assay conditions (reaction temperature, 
reaction time, and reagent concentrations). 
o Sub-objective 2.3: evaluate and compare the analytical performance 
characteristics of in-house real-time PCR assay and in-house LAMP 
assay. 
o Sub-objective 2.4: determine the performance characteristics of the 
assay (precision, analytical sensitivity, analytical specificity, and 
linearity).  
 
 Specific objective 3: Clinically validate both the in-house developed MRSA 
molecular assays. 





o Sub-objective 3.2: test the PCR assay on the patient specimens to assess 
the clinical sensitivity and specificity. 
o Sub-objective 3.3: test the LAMP assay on the patient specimens to 




Chapter 2: Literature Review  
MRSA Detection by PCR 
 The literature on the detection of MRSA by real-time PCR is extensive. Many 
studies explored gene targets, chemistries, and platforms. The utility of PCR assay is 
substantial, especially in critical cases where rapid detection has a significant impact 
on treatment and prognosis. For example, Chan et al. (2015) describe a workflow 
combining MALDI-TOF MS and a home-brew real-time PCR with melt-curve analysis 
for the rapid detection of MRSA and vancomycin-resistant enterococci (VRE) from 
colonies and, most importantly, blood culture bottles [50]. For the detection of MRSA 
in blood culture, they used a duplex real-time PCR targeting mecA and nuc for 
resistance and identification of S. aureus respectively [50]. The results of the workflow 
were 100% concordant with culture and antibiotic susceptibility testing and took only 
2.5 hours [50]. 
 Multiple publications are available assessing home-brew real-time PCR assay. 
The studies assessed various targets and conditions and their effects on the assay 
performance. Paule et al. (2004) designed a real-time PCR assay to detect S. aureus 
from neonatal nasal swabs by targeting the femA gene, a gene containing a conserved 
region in S. aureus [51]. They found that the assay sensitivity was higher with PCR 
(98%) than culture (90%). Additionally, the measured turn-around time of the assay 
was 2 hours.  
 The sensitivities and specificities of the in-house developed MRSA real-time 
PCR assays vary but are generally more sensitive and faster than culture. However, 
there are cases where culture was found to perform better. For example, Kali et al. 
(2014) compared home-brew PCR assay for the detection of mecA with commercial 
culture methods, including mannitol salt agar, MeReSA (HiMedia, India), and oxacillin 




and oxacillin screening agar compared to PCR; however, PCR had the superior 
specificity [52]. The lower sensitivity of the PCR was attributed to primer design and 
assay optimization. The point raises important issues when designing real-time PCR 
assays. The primer design process has to be stringent enough to increase specificity, but 
not too stringent as to reduce sensitivity. The stringency can be improved by exploring 
different amplification targets. The resistance marker mecA is widely used in in-house 
developed assays. However, these assays may have resulted in some false-negative 
results because of their inability to detect the newly emergent mecC gene. More recently 
developed assays, however, have incorporated the gene into the detection repertoire 
[53]. As for S. aureus specific genes, multiple targets have been proposed and used, 
including femA, 16S rRNA, nuc, and spa [50, 52, 54-58]. 
 With further development, more commercial assay kits became available in the 
market, and many researchers investigated their performance and compared them to 
each other. Examples of these kits are the FluroType® MRSA assay (Hain Lifescience), 
Xpert MRSA Gen 3 (Cepheid), BD-Max MRSA XT, BD StaphSR, BD GeneOhm [59-
62]. For MRSA detection, instead of multiple targets, many of the commercial kits 
target SCCmec, using primers directed towards the junction at which SCCmec is 
inserted into the S. aureus chromosome [53, 59-63]. The applications of PCR in the 
detection of MRSA are widely present and continuously developing. PCR offers 
potentially higher sensitivity and specificity, as well as faster turn-around times. It does 
come at a higher cost, however. Culture methods tend to be much cheaper than real-
time PCR due to the requirement for fluorescent probes, reaction reagents, and 
sophisticated instruments. An assessment of the cost of commercial assay could not be 
made from the literature, as the prices are seldom mentioned and they vary between 




other, an in-house developed assay tends to be much cheaper than commercial assays. 
However, it should be noted that the cost-effectiveness of an in-house developed PCR 
assay is highly dependent on how well it is designed and optimized. 
 
MRSA Detection by LAMP 
Since Notomi et al. ’s publication of LAMP in the year 2000, the technique has 
seen many applications, ranging from environmental surveys to diagnostics. Currently, 
2206 publications are available on LAMP in the PubMed database, many of which 
applied the technique for the detection of microorganisms. It has been applied for the 
detection of various human pathogens, including E. coli O157, L. monocytogenes, P. 
aeruginosa, Salmonella, V. parahaemolyticus, and Y. pseudotuberculosis [64]. A 
comprehensive search of publications in the databases: PubMed, SCOPUS and Web of 
Science using the terms “loop-mediated isothermal amplification” and “MRSA,” 
limited to publications related to human infection and those published in English, 
yielded 17 publications form the year 2000 (when the technique was developed and 
reported) to 2018 (Table 1). 
The first report of using LAMP for the detection of MRSA was in 2007 by 
Misawa et al. [65]. LAMP was applied to detect MRSA directly from positive blood 
cultures. The LAMP primers were designed to target the spa gene (protein A specific 
to S. aureus) and the mecA gene for methicillin-resistance [65]. The assay was 
compared to a duplex real-time PCR targeting the nuc and mecA genes. The limit of 
detection (LOD) of the assay was determined using serial 10-fold dilutions of an 
American Type Culture Collection (ATCC) MRSA strain and detection by a turbidity 
meter. By LAMP assay, the LOD of detecting spa and mecA genes were 103 and 102 
copies/reaction, respectively, compared to 10 copies/reaction for both the nuc and mecA 




common infectious pathogens, including MRSA, MSSA, methicillin-resistance 
coagulase-negative staphylococci (MRCoNS), methicillin-sensitive coagulase-
negative Staphylococci (MSCoNS), several enteric pathogens, Streptococcus 
pneumoniae, and many others. The LAMP assay was positive for spa in MRSA and 
MSSA only and positive for mecA in MRSA and MRCoNS only, giving the assay 100% 
specificity. When tested on blood cultures, the LAMP assay was found to have 
sensitivity, specificity, positive predictive value (PPV), and negative predictive value 
(NPV) of 92.3%, 100%, 100%, and 96.6%, respectively. PCR on the other hand, had 
96.2% sensitivity, 100% specificity, 100% PPV, and 98.4% NPV [65]. Thus, it can be 
concluded that the LAMP assay developed by Misawa et al. can detect MRSA from 
blood cultures with superior sensitivity and specificity, but the PCR assay was 
analytically more sensitive. However, the LAMP assay offers the advantage of being 
more practical and cheaper. One limitation of this comparison between PCR and LAMP 
was that each assay targeted different genes for S. aureus, and thus the differences may 
be due to the characteristics of the targets rather than the detection method. 
All the studies set out to develop a molecular assay that is more sensitive and 
rapid than culture methods. The studies investigated various amplification targets and 
specimen types. The most common targets used for S. aureus detection are spa and 
femA, with some studies using femB, and one study each using nuc and orfX. Most of 
the studies compared in-house developed PCR and LAMP assays. The LODs between 
the studies are not directly comparable because of the different units of measurements. 
Nevertheless, the majority of reports concluded that LAMP is at least ten times more 
sensitive than PCR. The amplification and detection platforms used in these studies are 
also different. One study is exceptional in that the results were evaluated based on 




under UV [66]. However, the LOD using this method was found to be ten times higher 
than conventional PCR, possibly because their extraction method was unable to remove 
LAMP inhibitors [66]. Other studies employed more sophisticated platforms such as 
microfluidics or surface plasmon resonance imaging (SPR) [67-70]. While these 
methods have been shown to work, they increase the cost of the assay with the 
requirement of expensive instruments and consumables. 
All the studies had the common goal of developing a cost-effective, rapid, and 
accurate assay. The majority of the studies evaluated LAMP on sterile fluids or clinical 
isolates, both of which typically contain fewer non-target organisms as opposed to the 
swab specimens used for screening. Also, all the in-house developed LAMP assays 
targeted only the mecA gene for antibiotic resistance. As detailed in the introduction, 
another resistance gene has emerged recently, the mecC gene. The exclusion of the 
mecC gene can lead to higher rates of false negatives. Because of that, there is a need 
to develop an assay that is sensitive, specific, and cost-effective, and targets both the 
mecA and mecC genes. Although there are commercial kits available that include the 
mecC gene [71, 72], they are still more expensive than an in-house developed assay. 
 
Table 1. LAMP Literature Review Summary 
Year  Target 
genes  









2007 spa, mecA Blood 
Culture 
103 and 102 
copy/reaction 
92.3 100 100 96.6 Misawa et 
al. [65] 
2010 spa, mecA plaque <400 and <4000 
CFU/ml 
100 100 100 100 Koide et al. 
[66] sputum 52.9% and 
69.2  




Year  Target 
genes  









2011 NM Swab 17 copy/ reaction NM NM NM NM Bearinger et 
al. [73] 
2011 spa, mecA Sputum and 
serum 
1-10 fg/µl NM 100% NM NM Wang et al. 
[67] 
2011 femB, mecA Culture NM NM NM 92.5 NM Hanaki et al. 
[74] 
2012 femA, mecA Culture 800 and 8000 
CFU/ml 
98.5 and 94.3 100 100 98.1 
and 
92.3 
Xu et al. 
[75] 
2014 femA, mecA Blood 
Culture 
NM 91.7% 100 100 100 Metwally et 
al. [76] 
2014 orfX Culture 400 CFU/ml NM 100 100 92.7 Su et al. [64] 
2015 spa, mecA Culture 103 CFU/ml NM 100 NM NM Guo et al. 
[68] 
2015 femA, mecA Culture 10 copies/µl NM NM NM NM Nawattanapa
iboon et al. 
[70] 




NM c NM c NM c NM c NM c Sudhaharan 




Year  Target 
genes  









2015 nuc, mecA Blood 
Culture 
<1.47 and <14.7 
pg/µl 
NM c 100 NM c NM c Wang et al. 
[78] 
2016 femB, mecA Blood 
Culture, 
Sputum 




iboon et al. 
[79] 





104 CFU/ml for 
16S rRNA, femA 
orfX 
105 CFU/ml for 
mecA 
97.2 NM NM NM Lin et al. 
[80] 
2017 nuc, femB, 
mecA 















NM 100 92.3 NM NM Rodel et al. 
[72] 
a. The LOD units could not be standardized, as many publications did not disclose the amplicon 
length. 
b. NM: not mentioned 
c. The specific values were not mentioned, but the results are reported to be identical to the PCR 




Chapter 3: Methods 
Real-time PCR primers and probes 
Primer and probe design 
 Novel primers and probes for real-time PCR were designed targeting the mecA 
and mecC genes to detect methicillin resistance, the staphylococcal coagulase gene, 
coa, to detect coagulase-positive Staphylococcus species, and the thermonuclease gene, 
nuc, specific to S. aureus. The primers and probes were designed using the Primer 
Express v3.0.1 software (Applied Biosystems™) using reference gene sequences 
obtained from the National Center for Biotechnology Information Reference Sequence 
database (NCBI RefSeq; Appendix A). 
 For each gene, the sequences were imported into the software primer/probe sets 
were automatically generated using the “Find primers/probe” feature under the 
“TaqMan Quantification” type and default parameters. The software generated a list of 
candidate primer/probe sets arranged by a penalty score. The software calculates the 
score based on various parameters, including length, GC-content, secondary structures, 
dimerization, etc. The sets with the lowest penalty score were assessed for hairpin 
structures, self-dimers, and cross-dimers using the software’s built-in features. One set 
for each of mecC, mecA, coa, and nuc were designed, and one set for each of mecA, 
coa, and 16S rRNA genes were retrieved from previously published literature by Hasan 
et al. (2013) [82]. To differentiate the two coa and mecA sets, they were numbered as 
CoA1 and mecA1 for the sets designed by Hasan et al. and CoA2 and mecA2 for the 
novel sets.  
 
Primer and probe assessment 
 The primer and probe specificities were assessed in silico using the NCBI 




nucleotide collection (nr/nt) database [83]. The BLAST search was conducted with the 
“somewhat similar sequences” algorithm to ensure comprehensiveness. The algorithm 
allows for more lenient sequence alignment and enables the comparison to less 
homologous sequences. The primer/probe sets meeting the conditions: 1) 
complementary to the target gene, 2) not complementary to other similar genes, were 
selected for further in silico analysis The assessment showed alignment to the target 
genes in S. aureus over the primer and probe regions for mecA, mecC, and coa. 
(Appendices C-F). The nuc forward primer and probe had single-nucleotide 
mismatches with some S. aureus strains. The mismatches were resolved by introducing 
mixed base pairs in the sequences.  
 The amplicon sequences, including the primers and probe annealing sites for 
each primer/probe set were generated from the reference sequences and used for further 
specificity assessment. Another BLAST search was conducted with the amplicon 
sequences against a sample of randomly selected genome sequences for multiple 
bacterial species, including various strains of S. aureus and other Staphylococcus 
species (Appendix B). The results were analyzed for the complementarity of the primer 
and probe regions on their target sequence. In the case of mecA and mecC, 
complementarity was sought for any species carrying the genes, for coa 
complementarity was sought for the coagulase gene in coagulase-positive 
staphylococci, and for nuc, complementarity was sought only for the gene in S. aureus. 
The primer/probe sets showed complementarity to their respective targets and no 
significant complementarity to other genomic. The novel sets and those previously 
published by Hasan et al. [82] were synthesized by Integrated DNA Technologies (IDT) 
and purified under standard de-salting conditions (Table 2). Because the intended 




fluorescent dyes. mecA and mecC used FAM and nuc, and 16S rRNA used Cy5. As for 
coa, each probe was synthesized in duplicate, one with ROX and the other with JOE. 
 











CoA1-F TAGATTGGGCAATTACATTTTGGAG   




CoA1-P CGCTAGGCGCATTAGCAGTTGCATC   
     
Novel 
CoA2-F TCGTTCAAGGTCCCGATTTT   




CoA2-P CAATGGAACAAAGCGGCCCATCA   
     
Hasan 
et al. 
mecA1-F GTAACATTGATCGCAACGTTC   








     




















     
Novel 
mecC-F GCAAGCAATAGAATCATCAGACAAC   

























     
Hasan 
et al. 
S16S-F TCGTGAGATGTTGGGTTAA   

















*Y: mixed nucleotide with C and T. 
 
 Finally, the primers were tested in-vivo against American Type Culture 
Collection (ATCC) strains, ATCC BAA 976 and ATCC BAA 1026, first, then against 
randomly collected MRSA clinical isolates. Figure 6 below shows the workflow of the 
primer design and assessment process. 
 
 








 The LAMP primers were designed using the open-source software Primer 
Explorer V5 (Eiken Chemical Co. Ltd.) targeting the same genes as the real-time PCR 
assay. The same reference sequences were used to design the primers, except for the 
coagulase gene, as initial testing of the PCR primers showed no amplification. The new 
reference sequence used for the coagulase gene is AJ306908.1 (Appendix A). The 
Primer Explorer software runs an algorithm that generates sets of primers with specific 
parameters for melting temperature (Tm), GC-content, and ΔG.  
 The primers for this study were designed using the default software parameters. 
The default parameters for Tm are 64-66°C for F1c and B1c, 59-61°C for F2 B2, and 
64-66°C for the loop primers and the default parameter for the GC content is 40-65% 
[49]. The reference sequences were uploaded to the software, and five candidate primer 
sets were generated for each gene under the default parameters. The software lists the 
primer sets along with the 3 and 5 stability in the form of ΔG. As per the software’s 
guidelines, primer set with the ΔG of the 3 ends of the F2 and B2 primers and the 5 
ends of the F1c and B1c be ≤ -4.0 kcal/mol were chosen. Then, primer data files were 
downloaded for each set and then re-uploaded into the software to generate compatible 
loop primers. The generated loop primers were evaluated based on the 3 ΔG and the 
loop primer sets with negative ΔG were selected and compared for the 5 ΔG. The loop 
primer sets with the lowest 3 and 5 ΔG for each set of primers were selected. Also, 
sets of primers for mecA and nuc were retrieved from the literature [78]. 
 
 




 The generated sets, including their loop primers, were assessed for hairpins, 
self-dimers, and cross-dimers using the AutoDimer V1 software (National Institute of 
Standards and Technology). Then each set was evaluated with BLAST. All primer sets 
were also synthesized by IDT for further in vitro assessment. All primers were purified 
by standard desalting. The processes of assessment with BLAST and in vitro testing 
were conducted similarly to the real-time PCR primers. Regardless of the result of the 
results of the specificity assessment, all primers were synthesized by IDT with standard 
desalting purification. Table 3 below contains the sequences of all the primers. 
 
Table 3. LAMP Primers 




























































































































Source Primer Sequence (53) 
nucL-LF GTATCACCATCAATCGCTTT 
























































 Two positive controls were used in this study, extracted DNA from an American 




a plasmid for the mecC gene. The ATCC strain was previously confirmed to be S. 
aureus by the Bruker MALDI-TOF Biotyper (Bruker, USA) and methicillin-resistant 
by BD Phoenix (Becton-Dickinson, USA). The isolate was cultured on sheep blood 
agar (BAP; International for Medical Equipment’s and Supplies, Qatar) and incubated 
at 35°C in a 5% CO2 incubator for 24 hours. Then, a 0.5 McFarland (McF) suspension 
was created in normal saline. The solution was then diluted into nine 10-fold serial 
dilutions. The fifth, sixth, and seventh dilutions were subsequently cultured on BAP in 
duplicate and incubated at 35°C in a 5% CO2 incubator for 24 hours. The colonies were 
counted and used to quantify the bacteria in the solution in CFU/ml (Figure 7). Finally, 
DNA was extracted from each dilution using NucliSENSE EasyMAG (Biomerieux, 
USA) magnetic silica-based automated extraction platform (Table 4). 
 
 
Figure 7. Positive control plates for mecA, nuc, and coa. 
The image on the left shows the fifth dilution, and the image on the right shows the sixth 
dilution. 
 
 Based on the experiments, more dilutions were required to specify the limit of 
detection of the assay. Thus, the positive control was further diluted 2-fold from PC4 




Table 4. Positive Control Quantification for mecA, nuc, and coa 


















 DNA from all the controls was extracted as described in the methods and used 
for testing. As for mecC, a plasmid containing the target sequence was synthesized by 
IDT. The plasmid was accompanied by a specification sheet that contained the mass of 





(𝑚𝑎𝑠𝑠 𝑜𝑓 𝐷𝑁𝐴 (𝑔) x Average number of base pairs per mole)
𝑙𝑒𝑛𝑔𝑡ℎ 𝑜𝑓 𝐷𝑁𝐴 x 𝑎𝑣𝑒𝑟𝑎𝑔𝑒 𝑚𝑎𝑠𝑠 𝑜𝑓 𝑜𝑛𝑒 𝑚𝑜𝑙𝑒 𝑜𝑓 𝑏𝑎𝑠𝑒 𝑝𝑎𝑖𝑟𝑠
 
 
 The mass of the plasmid, as specified by IDT, was 1.98x10-6g, and the length 
of the plasmid was 3078 bp. The average number of base pairs per mole is 6.02x1023 




calculated to be 5.96x1012 copy/µl. The concentration was confirmed by NanoDrop 
(Thermo Fisher Scientific, USA). The plasmid was serially diluted 10-folds and into 
ten dilutions, then 2-folds to make eight intermediary dilutions similar (Table 5). 
 
Table 5. mecC Plasmid Dilutions and Quantification 




















 In addition to the above, a new set of positive controls was created for the 
LAMP assay as the original controls were depleted. First, the DNA from 200µl of PC8 
was extracted in quadruplicate and eluted in 60µl each then mixed. The quantity 
calculation was adjusted to account for the further extraction then serially diluted. The 




Table 6. LAMP Positive Control Quantification (mecA, coa, and nuc) 


















Real-time PCR assay optimization 
Primer/probe initial verification 
 The initial verification of the real-time PCR reaction was performed using 
TaqMan™ Universal PCR Master Mix (Thermo Fisher Scientific, USA) in a 25µl 
reaction volume containing 1X TaqMan Universal PCR Master Mix, 0.3µM of the 
forward and reverse primers, 0.2 µM of the probe, and 5µl of the sample. The reaction 
was run in an Applied Biosystems® Fast Dx Real-Time PCR System (Thermo Fisher 
Scientific, USA) under the manufacturer's recommended conditions. The thermal 
cycling profile included an initial denaturation at 95°C for 10 minutes followed by 40 
cycles of 95°C denaturation for 15 seconds and 60°C annealing and extension for 1 




(1011 – 101 with 100-fold dilutions) along with a nuclease-free water sample as a 
negative control. For mecA, coa, nuc, and the 16S rRNA genes, the sets were verified 
against 0.5 McF and 10-fold dilutions of two ATCC MRSA strains, BAA 976 and BAA 




 Two master mixes, TaqMan™ Universal PCR Master Mix (henceforth 
abbreviate as TaqMan) and TaqPath™ 1-Step RT-qPCR Master Mix (Thermo Fisher 
Scientific, USA; henceforth abbreviated as TaqPath), were compared using all the 
primer sets to optimize the reaction. First, singleplex reactions were compared between 
both. For TaqMan, the reactions were performed using the same conditions as above. 
As for TaqPath, the reaction volume was 20µl containing 1X TaqPath™ 1-Step 
Multiplex Master Mix, 0.3µM of the forward and reverse primers, 0.2µM of the probe, 
and 5µl of the sample. The reaction was run under the manufacturer's recommended 
thermal cycling conditions, which is an initial denaturation at 95°C for 2 minutes 
followed by 40 cycles of 95°C denaturation for 3 seconds and 60°C annealing and 
extension for 30 seconds. The samples used were 0.5McF for the two ATCC strains 
BAA 976 and BAA 1026 and 105 copy/ml sample of the mecC plasmid. The best 
primer/probe sets were selected based on the previous two experiments and used to 
design a multiplex assay. The multiplex assays were run with both master mixes and 
using the same conditions as the singleplex assays. 0.3µM of each forward and reverse 
primers and 0.2µM of each probe were mixed into the reaction. The multiplex reactions 






 To further verify the primers and probes and assess their coverage of the local 
strain, the optimized multiplex real-time PCR reaction was performed with ten random 
clinical isolates collected from the Sidra Medicine Microbiology Laboratory. The 
isolates were confirmed MRSA positives by MRSA CHROM agar. A single colony 
was picked directly from the agar and re-suspended in Tris-EDTA (TE) buffer. The 
suspension was then diluted 105-fold and 106-fold. Both dilutions were used in the 
assay. The reaction was run using the multiplex assay with the TaqPath master mix 
under the manufacturer’s recommended conditions. 
 
LAMP assay optimization 
Primer/probe initial verification 
 The primer sets for the LAMP assay were verified using the same process as for 
the real-time PCR. First, a 10X primer mix was created for each set by mixing 16µM 
of each of FIP and BIP, 2µM of F3 and B3, and 4µM of each of the loop primer. The 
reactions were performed using the WarmStart® LAMP KIT (New England BioLabs, 
USA; henceforth abbreviated as WarmStart) in a 25µl reaction volume containing 1X 
WarmStart LAMP Master Mix, 1X of the fluorescent dye supplied with the kit, 1X 
primer mix, and 1µl of the sample DNA. The reactions were performed on an Applied 
Biosystems® Fast Dx Real-Time PCR System. The program used consisted of 30 
cycles at 65°C with detection at each cycle using the SYBR Green I channel. Melt curve 
analysis was performed following the reaction to confirm and compare the 
amplification results. The samples tested were extracted DNA from the two ATCC 
strains used for PCR, a plasmid containing mecC, and nuclease-free water as a negative 






 Similar to PCR, two master mixes were tested, the WarmStart® LAMP Master 
Mix and LavaLAMP™ DNA Master Mix (Lucigen, USA; henceforth abbreviated as 
LavaLAMP). The WarmStart reactions were run using the same reaction mixture as 
above. As for LavaLAMP, a reaction mixture of 25µl containing 1X LavaLAMP master 
mix, 1µl of the supplied fluorescent dye, 1X primer mix, and 1µl of the sample was 
used. The same temperature and time were used for the reaction, with the addition of a 
2-minute denaturation at 95°C. The master mix producing the best result was used for 
further reaction optimization in terms of primer mix concentration, and reaction 
temperature (Table 7). 
 




Reaction 1 Reaction 2 Reaction 3 Reaction 4 
65 1X 1.25X 1.5X 2X 
66 1X 1.25X 1.5X 2X 
67 1X 1.25X 1.5X 2X 
68 1X 1.25X 1.5X 2X 
69 1X 1.25X 1.5X 2X 
 
 All reactions were performed on the Applied Biosystems® Fast Dx 
Real-Time PCR System (Thermo Fisher Scientific, USA) using the SYBR Green I 
channel for detection. The samples tested were the same as those used in the initial 








 Patients in Sidra Medicine undergo risk-based screening for MRSA upon 
admittance to the hospital through the collection of swabs from the nares, throat, groin, 
and in newborns, the umbilical cord. MRSA screening specimens are cultured on 
MRSA CHROM agar and incubated at 35°C in a non-CO2 incubator. The culture plates 
are read after 24 hours of incubation, and the growth of pink colonies is interpreted as 
the presence of MRSA. Then, Bruker MALDI-TOF Biotyper (Bruker, USA) is used to 
confirm that the colony is S. aureus. Confirmation of the resistance is performed for 
isolates from cardiology patients by BD Phoenix (Becton-Dickinson, USA). At present, 
molecular testing for MRSA is reserved for urgent cases and is performed by the 
Cepheid Xpert MRSA Gen 3 kit. 
 For the present study, retrospective, residual swab (E-swabs and dry swabs, 
VWR, USA) specimens were collected from the Microbiology Laboratory in Sidra 
Medicine. Two-hundred specimens were collected, consisting of 122 E-swabs and 78 




 The collected clinical specimens were extracted using the NucliSENSE 
EasyMAG magnetic silica-based automated extraction platform. Dry swabs were 
immersed in 1mL of 1X PBS, pH 7.4 (gibco, Thermo Fisher Scientific; USA), and 
vortexed for 15 seconds to re-suspend the bacterial cells. As for E-swabs, the tube was 
vortexed for 15 seconds, and the solution was used for extraction. 600µl of the 
specimens were used for extraction under the generic protocol, following the 






Assay validation was performed following the recommendations of Burd’s 
(2010) paper, “The Validation of Laboratory-Developed Molecular Assays for 
Infectious Diseases.” The paper describes requirements and proposed experiments to 
validate assays following the Clinical Laboratory Improvement Amendments (CLIA) 
and the College of American Pathologists (CAP) [84]. The validation criteria are 
linearity and reportable range, analytical sensitivity (LOD), precision, analytical 
specificity, and accuracy. Linearity, analytical sensitivity, and precision were measured 
simultaneously using serial dilutions of quantified positive control tested in triplicates 
once a day for five days and recording the Ct for real-time PCR or the time-to-result 
(Tt) for LAMP. The experiment encompasses 15 data points for each dilution and 135 
data points for the experiment as a whole. The analytical specificity was assessed by 
testing the assays against a panel of bacterial organisms commonly isolated in the lab 
setting (Table 8). The panel was created by collecting colonies directly from culture 
plates after identification by MALDI-TOF. Finally, the accuracy was measured by 














Table 8. List of Organisms in the Specificity Panel 
Acinetobacter 
baumannii 






































   
 
Statistical analysis 
The data collected from the study was saved on an Excel spreadsheet for the 
initial organization and analysis. The linearity of the assays was measured with linear 
regression using a plot of log10 quantity vs. Ct (or Tt) and overlaying a best-fit line. The 
r2 value was used as the measure of linearity and was considered acceptable when r2 ≥ 
0.98. The reportable range of the assay was determined as the range of concentrations 
over-which the assay result was linear.  
Analytical sensitivity was measured as the LoD at 95% confidence by applying 
probit analysis [84]. In short, probit analysis is a specialized regression analysis for 
binomial variables. It is used in dose-response analysis to measure the lowest dose that 
will generate a response 95% of the time. As for the precision, the standard deviation 
(SD) between the replicates was measured for the same concentration of analytes.  




time) and inter-test (replicates over multiple different days). The precision of the assay 
was considered acceptable if 95% of the replicates fall within ±2 SD for all replicates 
or ±3 SD for replicates within 20% of the LoD. The specificity was calculated as the 
ratio of true positives to total positives, and the accuracy was calculated as the 
percentage of results in agreement with the chromogenic agar culture result. 
 
Ethical compliance 
 Ethical approval was obtained from the Institutional Review Board (IRB) of 
Sidra Medicine before collecting the clinical samples and conducting the experiments. 
The study involves the secondary use of residual anonymous biological materials that 
were previously collected for diagnostic purposes by the Microbiology laboratory. The 
patients’ identifiers and demographic information were not required. As such, each 
sample was given a serial number, and all patient identifiers were removed to ensure 
the specimen could not be linked back to the patients. The IRB at Sidra Medicine 





Chapter 4: Results 
Real-time PCR assay Verification and Optimization 
 The primer/probe sets designed for the real-time PCR assay were verified in 
vitro using the MRSA ATCC strains BAA 976 and BAA 1026 for the mecA, nuc, 16S 
rRNA, and CoA genes. While the pmecC plasmid was used to verify the mecC 
primer/probe set. Ideally, the mecC set would have been verified using a bacterial 
strain; however, no known mecC strains were available in the laboratory. The 
verification was conducted with both the TaqMan and TaqPath master mixes and using 
both the CoA sets labelled with ROX and the sets labelled with JOE. 
 mecC, mecA1, and mecA2 showed positive amplification with both master 
mixes, with mecA2 having consistently lower Cts than mecA1. As for the S. aureus 
specific targets, both nuc and 16S amplified in the samples. However, 16S also showed 
amplification in the negative control, suggesting non-specific amplification. Finally, 
only CoA1 showed amplification in both master mixes. CoA2 was negative for one of 
the control strains, ATCC BAA 1026, suggesting lack of coverage of S. aureus strains. 
 The comparison of the master mixes overall showed that TaqPath consistently 
performed better than TaqMan, owing to its optimization for multiplex reactions. 
Notably, the CoA1 set labelled with ROX performed worse than the one labelled with 
JOE in the TaqMan master mix, likely due to the presence of ROX as a passive dye.  
 Thus, the mecC, mecA2, CoA1, and nuc sets were chosen for the multiplex 
assay. From the results, the TaqPath master mix performed better and enables the 
addition of an extra internal control. Nevertheless, the multiplex reaction was tested 







Table 9. Multiplex Real-Time PCR: TaqMan vs. TaqPath 
Target Sample 
TaqMan TaqPath 
Ct1 Ct2 Ct1 Ct2 
mec 
ATCC BAA 976 25.13 27.53 23.99 23.97 
ATCC BAA 1026 25.69 25.97 25.09 25.35 
pmecC (105 copy/ml) 33.23 34.18 33.72 33.68 
H2O Negative Negative Negative Negative 
    
  
coa 
ATCC BAA 976 25.14 27.41 23.67 23.80 
ATCC BAA 1026 24.45 25.13 24.92 25.52 
pmecC (105 copy/ml) 38.62 38.75 Negative Negative 
H2O 32.36 22.31 Negative Negative 
     
nuc 
ATCC BAA 976 25.91 27.24 24.57 24.40 
ATCC BAA 1026 26.00 25.56 25.43 25.50 
pmecC (105 copy/ml) Negative Negative Negative Negative 
H2O Negative Negative Negative Negative 
      
IC 
ATCC BAA 976 26.15 24.76 20.53 25.28 
ATCC BAA 1026 23.96 23.40 25.37 22.63 
pmecC (105 copy/ml) 18.72 23.90 24.48 22.62 
H2O 22.62 21.37 27.23 19.38 
 
 Similar to the previous results, the TaqPath master mix also performed better. 
The coa target showed false-positive amplification in the negative control when using 
the TaqMan master mix, likely attributed to the presence of the ROX passive dye. As 
for the internal control, the criterion set by the laboratory was that it must be below a 
Ct of 33 to be considered acceptable. Based on this criterion, the internal control 
performed well with both the TaqMan and TaqPath master mixes. Then, to further 
verify the performance of the TaqPath master mix, and ensure no loss of sensitivity 
during the multiplex reaction, an experiment was performed to compare singleplex and 




Table 10. Singleplex vs. Multiplex Real-Time PCR with TaqPath. 
Target 
Sample Singleplex Multiplex 
 Average Ct Average Ct 
mec 
ATCC BAA 976 23.33 23.01 
ATCC BAA 1026 24.66 23.51 
pmecC (105 copy/ml) 30.99 31.52 
 H2O Negative Negative 
    
coa 
ATCC BAA 976 23.40 24.43 
ATCC BAA 1026 23.91 24.94 
pmecC (105 copy/ml) Negative Negative 
 H2O Negative Negative 
    
nuc 
ATCC BAA 976 25.48 25.72 
ATCC BAA 1026 26.81 26.10 
pmecC (105 copy/ml) Negative Negative 
 H2O Negative Negative 
    
IC 
ATCC BAA 976 
Not tested 
24.77 
ATCC BAA 1026 24.83 
pmecC (105 copy/ml) 22.95 
pmecC (105 copy/ml) Negative 
 
 The results of the singleplex and multiplex assays are all within 2 Cts of each 
other, showing no substantial loss of sensitivity. Thus, the assay was deemed 
satisfactory, and further optimization was not necessary. The final step of the evaluation 
was to test the multiplex assay against bacteria isolated from patients. The multiplex 
assay was positive for all targets on all ten isolates. Also, the Cts between the targets 
were close to each other. Which is expected, as all the targets exist on the bacterial 
chromosome, of which there is one copy. Thus, it was decided to continue with the 





Real-time PCR assay validation 
 The multiplex assay was tested with quantified controls to measure precision, 
sensitivity, linearity, and reportable range. The assay was found to be within the 
acceptance criteria in terms of precision (SD<2) and linearity (R2>0.98). The limits of 
detection were found to be 103 copy/ml for mecC, 103 CFU/ml for coa, and 104 CFU/ml 
for mecA and nuc. The detailed results of the experiment are presented in appendices G 
and H, and the plots for the linearity are shown in Figure 8.  
 
 

















Linear range: 103-1010  copy/ml






















Figure 8. Real-time PCR linearity plots 
 
 The specificity of the assay was tested using a panel of microorganisms, 
including MRSA, MSSA, CoNS, and other organisms commonly isolated in the 
laboratory. Amplification was observed for all targets with MRSA and mec in S. 
epidermidis and S. oralis, while all other organisms were negative for all targets, 
resulting in an apparent 100% specificity. Finally, the clinical specimens were tested 
with the assay to assess its accuracy by comparison with chromogenic agar and was 
found to be 95% (Appendix I). The assay’s performance characteristics are shown in 
















Linear range: 104 - 108 CFU/ml




































































a positive result was obtained for mec when testing against S. epidermidis and s. oralis. 
The assay was negative for all other targets, so it was considered as 100% specific 
because it was not S. aureus. 
 
LAMP Assay Verification and Optimization 
 The primer sets that met the design criteria were all tested to verify their 
function in vitro. In total, four sets for nuc, four sets for mecA, and four sets for coa. 
The mecC primer sets were not tested due to the unavailability of a positive control. 
The pmecC plasmid used for the real-time PCR assay was not compatible because of 
different target sequences. Of the tested primer sets, nuc3, nucL, and mecA1 showed 




remaining sets did not show any amplification. A melt curve analysis was performed to 
ensure that the amplification detected was from a single product (Figure 9). 
 
 
Figure 9. Melt curve plot for mecA1 LAMP primer set with ATCC 976 
 
 The three primer sets were then tested with the same ten clinical isolates used 
with the real-time PCR assay and showed positive amplification for all ten isolates. 
Nuc3 consistently showed a faster time to result than nucL. Thus, it was chosen for the 
assay. However, when the sets were tested with the positive control dilutions, positive 
amplification was observed down to L3 dilution (3.32x106 CFU/ml) for both targets. 
The assay was repeated using both the WarmStart and LavaLAMP master mixes with 
primer concentrations of 1X, 1.5X, and 2X and temperatures of 65, 68, and 70°C with 
no improvement to the results. 
 The sensitivity of the primers was assessed by performing a PCR reaction with 




electrophoresis using the positive control with the highest concentration (L1) and a 
negative control (Figure 10). The gel showed no bands for both mecA1 and nuc3 with 
the positive control L1, which suggests that the primers had reduced sensitivity. 
 
 
Figure 10. Gel picture of the mecA1 and nuc3 outer primers in a PCR reaction 
From left to right: lanes 2 and 3 contained the reactions of mecA1 F3 and B3 with L1 
and negative control, respectively. The expected size of the fragment is 210bp. Lanes 4 
and 5 contained the reactions of nuc3 F3 and B3 with L1 and negative control, 
respectively. The expected fragment size is 248bp Lane 6 contains a DNA ladder. 
  




Chapter 5: Discussion 
Designing a Molecular Assay 
 The process of developing an in-house molecular assay to detect or identify a 
pathogenic microorganism - PCR, LAMP, or any other technique - starts with the 
question of what should be detected. The primary aim of the present study is to develop 
PCR and LAMP assays to detect MRSA in patient specimens. The assay must be 
sensitive and specific enough, so it does not produce false-negative and false-positive 
results. In order to design these assays, first, it was essential to determine which genetic 
regions to target. 
 A search of the literature showed various possible target genes. Many of the 
developed assays use SCCmec or orfX as targets for MRSA detection. However, these 
two genes show variability between MRSA strains and may fail to detect some MRSA 
cases [85-87]. To date, there are eleven recognized SCCmec types based on sequence 
variation, with two more proposed in the literature [88]. The variation in the SCCmec 
region extends to orfX, leading to many of the available assays producing false 
negatives. A study evaluating PCR assays for the detection of MRSA in Denmark 
showed that the tested assay, which targets SCCmec, gave 15.4% false negatives [89]. 
Moreover, there are cases where SCCmec is present without methicillin resistance. Such 
SCCmec elements do not carry a mec gene; rather they carry resistance markers for 
other substances [90]. Targeting those elements, in turn, would produce false-positive 
results. The variability of SCCmec introduces uncertainty in testing, which would 
significantly impact the workflow of a clinical laboratory and might increase the cost 
of testing with the need for follow up confirmatory tests, especially if there is a clinical 
indication of MRSA. 
 Thus, instead of targeting SCCmec or orfX, this assay targets the more 




for the majority of resistance. However, the recently emergent mecC confers similar 
resistance. Thus, both of these were considered as targets for the assays. However, these 
genes are also harbored by species other than S. aureus. Therefore, it was integral to 
add a target that is specific to S. aureus. Existing literature includes many suggested 
targets, spa, nuc, femA, femB, among others for S. aureus. The target genes chosen for 
the assay were nuc, coa, mecA, and mecC so that PCR detects MRSA, as well as provide 
more information. Specifically, the targets were chosen such that the result can be 
interpreted as MRSA, MSSA, methicillin-resistant coagulase-negative staphylococci 
(MR-CoNS), methicillin-sensitive coagulase-negative staphylococci (MS-CoNS), 
methicillin-resistant or sensitive coagulase-positive staphylococci other than S. aureus, 
or a mixture of the above. While some of the results may not be useful to screening 
tests (i.e., CoNS), they could be significant when applied to sterile-site samples in the 
appropriate clinical context. 
 While designing the assay, one consideration was the creation of a multiplex 
reaction. An internal control (IC) was planned to be incorporated into the multiplex 
reaction to conform with regulatory requirements. Furthermore, to maintain 
consistency between the assays performed in the laboratory at Sidra Medicine and to 
prevent additional costs of synthesizing a new IC, it was decided to use the same IC 
used in the other assays. To that extent, the dyes on the five probes (mecA, mecC, coa, 
nuc, and IC) were chosen to minimize overlap between their spectra. The same color 
dye, FAM, was chosen for mecA and mecC because it was not necessary to differentiate 
between them. The nuc and 16S rRNA probes were synthesized with the Cy5 dye. As 
for CoA, it was synthesized in duplicate, one with the ROX dye and the other with the 
JOE dye. The reason is to assess the performance of the assay with both of the used 




coa probe with the JOE dye was used in its reaction, which prevented the use of the IC. 
TaqPath, on the other hand, lacks the passive reference dye, enabling the incorporation 
of the IC with the use of the ROX labeled coa probe. 
 Designing the LAMP assay was more challenging as the software does not offer 
sufficient resources or guidance on how to set and optimize the parameters. Also, due 
to the nature of the amplification reaction in LAMP and the vast array of structures that 
form, it is challenging to create a multiplex reaction. Also, regular practice is to use 
SYBR Green chemistry rather than probes for detection. Thus, no probes were designed 
for the assay. Furthermore, to account for the fact that LAMP is not as well established 




 The assay validation was performed following Burd’s (2010) paper. The 
performance characteristics passed the set criteria for precision and linearity of the 
assay. While the assay is qualitative, the establishment of the linear range allows 
quantification by using quantitation standards. After the performance criteria were 
deemed satisfactory, the assay was evaluated using 200 screening specimens collected 
from the Microbiology Laboratory. At a glance, the assay would have low accuracy 
(Appendix I), due to the nature of the specimen. Because the specimens were swabs of 
body sites that typically contain a mixture of bacteria, including S. aureus and other 
methicillin-resistant CoNS It would be expected that a large portion of the specimen 
would have a positive result for mec and thus, the results must be interpreted with this 
in mind. 
 First, all three targets, mec, coa, and nuc, must be positive in MRSA. The coa 




positive result excludes the presence of CoNS. The nuc gene then differentiates S. 
aureus from other coagulase-positive species, and, finally, the mec gene differentiates 
MRSA from MSSA. Thus, having all three genes increases the probability that the 
organism detected is MRSA. The probability would be very high in more invasive 
infections, where the specimen is less likely to have multiple species present. In the 
case of screening samples, however, there would likely be a mixture of species, which 
complicates the interpretation. For instance, how can the test differentiate if there was 
MRSA or a mixture of MSSA and MR-CoNS? 
 Further investigation of the results shows that there are differences in the Ct 
values in those cases. Therefore, a second criterion must be implemented in the 
interpretation. Because MRSA would possess a mec gene, coa gene, and nuc gene, and 
all three are in the chromosome, it is expected that all three would be present at similar 
levels to each other, assuming equal efficiency of amplification for each target. The 
cases that were positive for all three targets by the real-time PCR assay, but were MRSA 
negative by chromogenic culture consistently had a Ct difference greater than two 
between the average of nuc and coa and the Ct of mec. Accordingly, the criteria for a 
positive MRSA interpretation of the results are 1) all three targets are positive, and 2) 
the difference between the average Ct of coa and nuc and the Ct of mec is less than 2. 
Implementing these two criteria increases the accuracy from approximately 85% to 
96.25%. The accuracy is after the adjusted interpretation is consistent with published 
MRSA assays and commercial kits. Furthermore, accuracy ≥ 95% is acceptable to 
diagnostic laboratories and CLIA and Cap requirements. 
 Nevertheless, the assay does suffer from limitations. While it is useful in 
screening for MRSA and differentiating other groups of species with high accuracy, it 




MSSA and MR-CoNS are present at similar levels. In this case, differentiation is 
difficult, as it would meet the interpretation criteria. Similarly, a false negative result 
can occur when MR-CoNS are present in large quantities, which can cause the Ct for 
mec to be much lower than nuc and coa and thus not meeting the interpretation criteria. 
Six false positive and six false negatives were found in this study; however, it is 
unknown if the reason is the quantity of MR-CoNS present, a limitation of the assay, 
or differences in the sensitivities of the PCR and chromogenic agar.  
 By considering all the results, the assay is very useful in the detection of MRSA 
in invasive infections or from sterile body sites (e.g., blood). It is also useful for 
screening purposes; however, there are some limitations. The assay detects multiple 
organisms, MSSA, MRSA, MS-CoNS, and MR-CoNS. Giving it an advantage over 
other assays described in the literature, which detect MRSA or MSSA and MRSA [50-
62]. The wider detection range is particularly helpful in cases of blood infection. 
Finally, being an in-house developed assay, it reduces the testing cost compared to 
commercial assays. Currently, in Sidra Medicine, MRSA detection is performed using 
the Cepheid Xpert MRSA Gen 3 kit, which costs an approximate $100 per specimen. 
The present assay costs approximately $3 per sample for the primers, probes, and PCR 
reagents. The extraction cost can vary; in the case of this study, the extraction cost was 
an approximate $15, bringing the total cost per specimen to $18. Thus, the present assay 
reduces the cost of molecular MRSA detection by up to 80%. 
 
LAMP 
 While the primers designed for LAMP met the design criteria and showed 
promise when assessed in silico, they did not perform well in vitro. The primers resulted 




clinical isolates. However, these samples contained large amounts of bacteria. When 
tested with dilutions of the positive control, the limit of detection was found to be 
3.32x106 CFU/ml, which is contradictory to the literature as LAMP reactions were 
found to be at least 10-times more sensitive than PCR. Further investigation was 
conducted by testing the outer primers with a PCR reaction. The lack of bands on the 
agarose gel further supported the fact that the primers were not sensitive. Attempts to 
increase the primer concentrations were also unsuccessful in improving the sensitivity 
of the assay.  
 The low sensitivity can be due to various reasons. A scan of the available 
literature revealed that the recommendation is that the primers be purified with HPLC. 
The primers used in this study were purified with standard desalting, which yields lower 
purity than HPLC. Another possible explanation could be inherent to the primers 
themselves. Redesigning the primers with criteria that are more stringent and different 





Chapter 6: Conclusion 
 The present study aimed to develop a sensitive and cost-effective molecular 
assay for the detection of MRSA. The study had three objectives, to develop a real-time 
PCR assay, to develop a LAMP assay, and to validate the assays for use in clinical 
laboratories. The real-time PCR assay had 95% accuracy, >95% specificity and high 
precision. The assay was validated following the recommendations of Burd (2010) for 
the validation of in-house developed molecular assays following CLIA. The assay has 
the advantage of lower cost than the available commercial methods and a wider range 
of detection (MRSA, MSSA, MR-CoNS, and MS-CoNS) compared to other laboratory-
developed assays. 
 Nevertheless, it can be improved further to increase its utility. At present, it is 
suitable as a detection method in specimens where polymicrobial infections are 
uncommon. For screening, however, it suffers from the limitations outlined above. 
Multiple tweaks to the methodology can be investigated to alleviate some of these 
limitations and increase utility. First, the concentrations of the primer/probe sets in the 
multiplex reactions can be further optimized to increase sensitivity. For instance, the 
sensitivity of the nuc set was consistently slightly lower than the sensitivities of the 
other targets. Perhaps experimenting with increased proportions of the set can yield 
higher sensitivity. Similarly, experimenting with other proportions of the sets could 
fine-tune the results. Second, to reduce the probabilities of false results, more testing of 
clinical isolates and comparison with other methods should be conducted to tune the 
interpretation algorithm further. To increase the accuracy and specificity of the assay, 
one solution is to use orfX for the detection of methicillin-resistance and S. aureus 
simultaneously. Using orfX will also reduce the necessary targets, as mecA, nuc, and 




the result. Finally, the PCR reaction with the TaqPath master mix takes approximately 
40 minutes. The reaction includes two minutes of UNG incubation, 15 minutes of 
reverse transcription, and 22 minutes for the thermal cycling. The time can be shortened 
to 22 minutes by omitting the UNG incubation and reverse transcription; however, there 
will be a trade-off between time and sensitivity and specificity. Using the assay with 
other master mixes might provide a solution to minimize the trade-off, but will require 
investigation. Another major factor in the turn-around time (from specimen reception 
to result) is DNA extraction. This study used the NucliSENSE EasyMAG extraction 
platform; however, other extraction methodologies can be used, some of which might 
reduce the total time needed. As for cost, while made-to-order primers and probes are 
cheaper than commercial kits, the cost of the instrumentation can be a problem. Hence, 
it is up to the laboratory to choose between time and cost.  
 As for the developed LAMP, it had low sensitivity (limit of detection= 106 
CFU/ml). The reasons for the low sensitivity range from the design of the primers to 
the conditions at which they were synthesized. In both assays, further investigations 
may improve the results. For the LAMP assay, a better understanding of the mechanism 
and the factors that affect it, such as inhibitory molecules, can improve the design 
workflow. As can be seen in the study, the LAMP assay design is not as well established 
as PCR assays. With PCR, there exists a well-defined workflow with various software 
dedicated to the design of the primers for many purposes. Additionally, the expertise in 
PCR is widespread, and resources are plentiful. LAMP is a relatively recently 
developed technique and as of yet, a relatively less applied technique in infectious 
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APPENDIX B: In silico Specificity Reference Sequences 
 
NCBI Accession Organism 
NZ_CP009623.1 Staphylococcus agentis strain 908 
NC_016941.1 Staphylococcus argenteus MSHR1132 
NZ_CP025023.1 Staphylococcus argenteus strain XNO106 
NZ_CP010296.1 Staphylococcus aureus strain 31b_MRSA 
NZ_CP014791.1 Staphylococcus aureus Strain MCRF184 
NZ_CP019117.1 Staphylococcus aureus strain SJTUF_J27 
NC_017340.1 Staphylococcus aureus 04-02981 
NZ_CP025395.1 Staphylococcus aureus O46 
NZ_CP009361.1 Staphylococcus aureus strain ATCC 25923 
NZ_CP010402.1 Staphylococcus aureus strain GR2 
NZ_CP020020.1 Staphylococcus aureus strain ATCC 6538 
NZ_CP022290.1 Staphylococcus aureus strain EDCC5458 
NZ_CP022291.1 Staphylococcus aureus strain EDCC5464 
NZ_CP029031.1 Staphylococcus aureus strain CTI 
NC_022226.1 Staphylococcus aureus strain CN1 
NC_002951.2 Staphylococcus aureus strain COL 
NZ_CP011526.1 Staphylococcus aureus strain DSM 20231 
NC_009632.1 Staphylococcus aureus strain JH1 
NC_009487.1 Staphylococcus aureus strain JH9 
NC_017338.1 Staphylococcus aureus strain JKD6519 
NC_002758.2 Staphylococcus aureus strain Mu50 




NCBI Accession Organism 
NC_017341.1 Staphylococcus aureus strain JKD6008 
NZ_CP012409.1 Staphylococcus aureus strain Tager 104 
NZ_CP007601.1 Staphylococcus capitis strain AYP1020 
NZ_CP016760.1 Staphylococcus carnosus strain LTH 3730 
NZ_CP015114.1 Staphylococcus condiment strain DSM 11674 
NZ_CP018776.1 Staphylococcus condiment strain StO 2014-01 
NZ_CP009046.1 Staphylococcus epidermidis strain SEI 
NZ_CP020463.1 Staphylococcus epidermidis strain 1457 
NZ_CP022247.1 Staphylococcus epidermidis strain ATCC 12228 
NZ_CP018842.1 Staphylococcus epidermidis strain 14.1.R1 
NC_004461.1 Staphylococcus epidermidis strain ATCC 12228 
NC_002976.3 Staphylococcus epidermidis strain RP62A 
NZ_CP013114.1 Staphylococcus equorum strain KS1039 
NZ_CP013980.1 Staphylococcus equorum strain KM1031 
NZ_CP027770.1 Staphylococcus felis strain ATCC 49168 
NZ_CP013911.1 Staphylococcus haemolyticus strain S167 
NZ_CP025396.1 Staphylococcus haemolyticus strain 83131B 
NZ_CP024809.1 Staphylococcus haemolyticus strain 83131A 
NZ_CP025031.1 Staphylococcus haemolyticus strain SGAir0252 
NZ_CP027846.1 Staphylococcus kloosii strain ATCC 43959 
NZ_CP014022.1 Staphylococcus lugdunensis strain FDAARGOS_141 
NC_013893.1 Staphylococcus lugdunensis strain HKU09-01 
NC_017353.1 Staphylococcus lugdunensis strain N920143 




NCBI Accession Organism 
NZ_CP017460.1 Staphylococcus nepalensis strain JS1 
NZ_CP017463.1 Staphylococcus pasteuri strain JS7 
NC_022737.1 Staphylococcus pasteuri strain SP1 
NZ_CP016072.1 Staphylococcus pseudintermedius strain NA45 
NZ_CP016073.1 Staphylococcus pseudintermedius strain 081661 
NZ_CP015626.1 Staphylococcus pseudintermedius strain 063228 
NC_017568.1 Staphylococcus pseudintermedius strain ED99 
NC_014925.1 Staphylococcus pseudintermedius strain HKU10-03 
NC_007350.1 Staphylococcus saprophyticus strain ATCC 15305 
NZ_CP010309.1 Staphylococcus schleiferi strain 2317-03 
NZ_CP009762.1 Staphylococcus schleiferi strain 2142-05 
NZ_CP009676.1 Staphylococcus schleiferi strain 5909-02 
NZ_CP009470.1 Staphylococcus schleiferi strain 1360-13 
NZ_AP014944.1 Staphylococcus schleiferi strain TSCC54 
NZ_CP018199.1 Staphylococcus succinus strain 14BME20 
NC_020164.1 Staphylococcus warneri strain SG1 
NZ_CP007208.1 Staphylococcus xylosus strain HKUOPL8 
NZ_CP008724.1 Staphylococcus xylosus strain SMQ-121 






APPENDIX C: Novel Real-Time PCR coa Primer/Probe Sequence Alignment for 





Query       1        TCGTTCAAGGTCCCGATTTTCTAACAATGGAACAAAGCGGCCCATCATTAAGCAATAATTATACAAACCCACCG  74 
CP031661.1  212331   ..........................................................................  212404 
CP031670.1  232946   ..........................................................................  233019 
CP031664.1  212331   ..........................................................................  212404 
CP031673.1  214306   ..........................................................................  214379 
CP031667.1  232946   ..........................................................................  233019 
CP022910.1  212311   ..........................................................................  212384 
CP022908.1  250353   ..........................................................................  250426 
CP022906.1  250353   ..........................................................................  250426 
CP022902.1  250353   ..........................................................................  250426 
CP022892.1  212310   ..........................................................................  212383 
LS483319.1  235311   ..........................................................................  235384 
LS483316.1  236019   ..........................................................................  236092 
LS483301.1  260862   ..........................................................................  260935 
LS483365.1  212368   ..........................................................................  212441 
CP029664.1  2436153  ..........................................................................  2436080 
CP029678.1  266092   ..........................................................................  266165 
CP029667.1  2570180  ..........................................................................  2570107 
CP029669.1  1978415  ..........................................................................  1978342 
CP029166.1  246416   ..........................................................................  246489 
CP029032.1  267562   ..........................................................................  267635 
CP029030.1  267562   ..........................................................................  267635 
CP029031.1  267562   ..........................................................................  267635 
CP027101.1  2002719  ..........................................................................  2002646 
CP027476.1  267559   ..........................................................................  267632 
CP012119.2  2292025  ..........................................................................  2292098 
CP026962.1  354305   ..........................................................................  354378 
CP026961.1  1094306  ..........................................................................  1094379 
CP026960.1  2374652  ..........................................................................  2374725 
CP016858.2  1113219  ..........................................................................  1113146 
CP016855.2  1803936  ..........................................................................  1803863 
CP007539.3  2137715  ..........................................................................  2137642 




CP026077.1  952476   ..........................................................................  952549 
CP026076.1  1114607  ..........................................................................  1114680 
CP026072.1  1399855  ..........................................................................  1399782 
CP026070.1  823364   ..........................................................................  823291 
CP026068.1  2410506  ..........................................................................  2410579 
CP012120.2  1104379  ..........................................................................  1104306 
CP017094.2  1809782  ..........................................................................  1809709 
CP016861.2  1104378  ..........................................................................  1104305 
CP025495.1  1104378  ..........................................................................  1104305 
CP016863.2  2687172  ..........................................................................  2687099 
CP022290.1  210693   ..........................................................................  210766 
CP023500.1  2727892  ..........................................................................  2727965 
CP023391.1  212868   ..........................................................................  212941 
CP023390.1  212868   ..........................................................................  212941 
AP014921.1  234758   ..........................................................................  234831 
CP019590.1  268244   ..........................................................................  268317 
CP020619.1  267787   ..........................................................................  267860 
CP014444.1  267401   ..........................................................................  267474 
CP014441.1  267399   ..........................................................................  267472 
CP014438.1  267399   ..........................................................................  267472 
CP014435.1  267397   ..........................................................................  267470 
CP014432.1  267399   ..........................................................................  267472 
CP014429.1  267397   ..........................................................................  267470 
CP014426.1  267397   ..........................................................................  267470 
CP014423.1  267397   ..........................................................................  267470 
CP014420.1  267397   ..........................................................................  267470 
CP014415.1  267401   ..........................................................................  267474 
CP014412.1  267397   ..........................................................................  267470 
CP014409.1  267397   ..........................................................................  267470 
CP014407.1  267401   ..........................................................................  267474 
CP014402.1  267321   ..........................................................................  267394 
CP014397.1  267321   ..........................................................................  267394 
CP014392.1  267321   ..........................................................................  267394 
CP014387.1  267321   ..........................................................................  267394 
CP014384.1  267356   ..........................................................................  267429 
CP014381.1  267397   ..........................................................................  267470 
CP014371.1  267321   ..........................................................................  267394 
CP014368.1  267397   ..........................................................................  267470 
CP014365.1  267278   ..........................................................................  267351 
CP014362.1  267278   ..........................................................................  267351 
CP014376.1  267321   ..........................................................................  267394 
CP009423.1  267278   ..........................................................................  267351 




CP018205.1  212890   ..........................................................................  212963 
AP017377.1  248942   ..........................................................................  249015 
LT598688.1  212861   ..........................................................................  212934 
CP013231.1  2172073  ..........................................................................  2172146 
CP007676.1  233217   ..........................................................................  233290 
CP007672.1  257132   ..........................................................................  257205 
CP007657.1  236894   ..........................................................................  236967 
CP007657.1  257691   ..........................................................................  257764 
CP007674.1  240684   ..........................................................................  240757 
CP007670.1  256996   ..........................................................................  257069 
CP011526.1  212090   ..........................................................................  212163 
CP010300.1  267564   ..........................................................................  267637 
CP010299.1  267564   ..........................................................................  267637 
CP010298.1  267563   ..........................................................................  267636 
CP010297.1  267564   ..........................................................................  267637 
CP010296.1  267564   ..........................................................................  267637 
CP010295.1  267564   ..........................................................................  267637 
CP007499.1  245816   ..........................................................................  245889 
CP007690.1  267456   ..........................................................................  267529 
CP007176.1  268276   ..........................................................................  268349 
HF937103.1  264602   ..........................................................................  264675 
CP003033.1  212890   ..........................................................................  212963 
AB489885.1  1160     ..........................................................................  1233 
AB489883.1  1160     ..........................................................................  1233 
AB489874.1  1148     ..........................................................................  1221 
AB489873.1  1160     ..........................................................................  1233 




APPENDIX D: Novel Real-Time PCR mecA Primer/Probe Sequence Alignment 





Query       1        TTAGATTGGGATCATAGCGTCATTATTCCAGGAATGCAGAAAGACCAAAGCATACATATTGAAAATTTAAAATCAGAACGTGGTAAAATTTTAGACCGAAACAATGTGGAAT  
112 
CP031779.1  45152    ................................................................................................................  45041 
CP031537.1  1601507  ................................................................................................................  1601396 
CP022905.1  40763    ................................................................................................................  40652 
CP022908.1  40691    ................................................................................................................  40580 
CP022906.1  40691    ................................................................................................................  40580 
CP022904.1  40763    ................................................................................................................  40652 
CP022903.1  40763    ................................................................................................................  40652 
CP022902.1  40691    ................................................................................................................  40580 
CP022894.1  40763    ................................................................................................................  40652 
CP022893.1  40763    ................................................................................................................  40652 
CP031131.1  44502    ................................................................................................................  44391 
LT992477.1  1662989  ................................................................................................................  1663100 
LT992476.1  176025   ................................................................................................................  176136 
LT992475.1  2423162  ................................................................................................................  2423273 
LT992474.1  632787   ................................................................................................................  632676 
LT992473.1  1868717  ................................................................................................................  1868828 
LT992472.1  985333   ................................................................................................................  985222 
LT992471.1  91457    ................................................................................................................  91346 
LT992470.1  1772428  ................................................................................................................  1772539 
LT992469.1  2249342  ................................................................................................................  2249453 
LT992468.1  1364086  ................................................................................................................  1363975 
LT992467.1  1426438  ................................................................................................................  1426327 
LT992466.1  227147   ................................................................................................................  227258 
LT992465.1  1690005  ................................................................................................................  1690116 
LT992464.1  2638320  ................................................................................................................  2638431 
LT992463.1  232902   ................................................................................................................  232791 
LT992462.1  2614889  ................................................................................................................  2614778 
LT992461.1  1000036  ................................................................................................................  999925 
LT992460.1  923512   ................................................................................................................  923623 
LT992458.1  564210   ................................................................................................................  564321 
LT992456.1  1272784  ................................................................................................................  1272895 
CP030326.1  39812    ................................................................................................................  39701 
MH188482.1  17127    ................................................................................................................  17016 
MH188467.1  10841    ................................................................................................................  10730 
CP030323.1  453890   ................................................................................................................  454001 
MF774211.1  145      ................................................................................................................  256 
LS483319.1  40836    ................................................................................................................  40725 
LS483316.1  42876    ................................................................................................................  42765 
LS483309.1  87510    ................................................................................................................  87399 
LS483301.1  39799    ................................................................................................................  39688 
LS483484.1  46037    ................................................................................................................  45926 
CP029673.1  45158    ................................................................................................................  45047 
CP029664.1  2632451  ................................................................................................................  2632340 




CP029657.1  45158    ................................................................................................................  45047 
CP021171.1  42529    ................................................................................................................  42418 
CP021141.1  41377    ................................................................................................................  41266 
CP029680.1  2499821  ................................................................................................................  2499932 
CP029681.1  2373863  ................................................................................................................  2373974 
CP029655.1  518324   ................................................................................................................  518435 
CP029658.1  93474    ................................................................................................................  93585 
CP029678.1  40224    ................................................................................................................  40113 
CP029649.1  1747793  ................................................................................................................  1747904 
CP029675.1  46116    ................................................................................................................  46005 
CP029667.1  2796949  ................................................................................................................  2797060 
CP029669.1  2205161  ................................................................................................................  2205272 
CP029653.1  48546    ................................................................................................................  48435 
CP029652.1  1637884  ................................................................................................................  1637995 
CP015447.2  78441    ................................................................................................................  78330 
CP029172.1  48683    ................................................................................................................  48572 
CP029166.1  42052    ................................................................................................................  41941 
MF185206.1  4665     ................................................................................................................  4554 
CP029087.1  45158    ................................................................................................................  45047 
CP029086.1  1377533  ................................................................................................................  1377422 
CP029082.1  843862   ................................................................................................................  843973 
CP029080.1  505508   ................................................................................................................  505397 
CP029032.1  40761    ................................................................................................................  40650 
CP029030.1  40761    ................................................................................................................  40650 
CP029031.1  40761    ................................................................................................................  40650 
MF383340.1  196      ................................................................................................................  307 
CP020544.1  45797    ................................................................................................................  45686 
CP021105.1  42587    ................................................................................................................  42476 
CP020553.1  48473    ................................................................................................................  48362 
CP028190.1  904738   ................................................................................................................  904627 
CP028163.1  453460   ................................................................................................................  453571 
MG787423.1  7731     ................................................................................................................  7620 
CP027486.1  40969    ................................................................................................................  40858 
CP027101.1  2227741  ................................................................................................................  2227852 
CP027476.1  40761    ................................................................................................................  40650 
MG674089.1  24813    ................................................................................................................  24924 
MF278654.1  1673     ................................................................................................................  1562 
MF278653.1  1661     ................................................................................................................  1550 
CP012119.2  2065305  ................................................................................................................  2065194 
CP025031.1  879787   ................................................................................................................  879898 
CP026968.1  2723285  ................................................................................................................  2723174 
CP026958.1  1157965  ................................................................................................................  1158076 
CP026957.1  2093267  ................................................................................................................  2093378 
CP026953.1  1317804  ................................................................................................................  1317693 
CP016858.2  1339966  ................................................................................................................  1340077 
CP016855.2  2031446  ................................................................................................................  2031557 
CP007539.3  2343240  ................................................................................................................  2343351 
CP014119.1  1040946  ................................................................................................................  1041057 
CP014107.1  1760952  ................................................................................................................  1760841 
CP026074.1  1401227  ................................................................................................................  1401116 
CP026064.1  1417047  ................................................................................................................  1417158 
CP025396.1  70801    ................................................................................................................  70912 
CP024809.1  70801    ................................................................................................................  70912 
CP026079.1  826739   ................................................................................................................  826850 
CP026073.1  2081857  ................................................................................................................  2081968 
CP026072.1  1602957  ................................................................................................................  1603068 




APPENDIX E: Novel Real-Time PCR mecC Primer/Probe Sequence Alignment 





Query        1        GCAAGCAATAGAATCATCAGACAACATATTTTTTGCCCGCATTGCATTAGCATTAGGAGCCAAAAAATTTGAGCAAGGTATGCAAGA  87 
CP028165.1   1562939  .......................................................................................  1562853 
NG_047955.1  1459     .......................................................................................  1545 
KU867950.1   16862    .......................................................................................  16948 
KR732654.1   2623     .......................................................................................  2537 
KT192641.1   1359     .......................................................................................  1445 
LK024544.1   5173     .......................................................................................  5087 
HF569116.1   2380     .......................................................................................  2294 
KC110686.1   1237     .......................................................................................  1323 
JN794592.1   151      .......................................................................................  237 
FR821779.1   36320    .......................................................................................  36234 
FR823292.1*   2380     .......................................................................................  2294 
KF955540.2  1794     ....................................A..T...........T........T..........................  1880 
HG515014.1   43635    .....................T..T..T.............................G..T..........................  43549 
HG515014.1   12528     ....................T.....T..C.....TA.AG.A...C.C.A......CAGT..G........AA....C...A..    12445 
HE993884.1   12672    ............G.......................A..T...........T.....C..T..........................  12586 
MH155596.1   120181   .....................T..............A..T...........T........T............A........A....  120095 
MG334392.1   60       ............G.................A.....A..T....................                             1 
MG334391.1   60       ............G.................A.....A..T....................                             1 
NG_047950.1  1379      .....T..T...........T..T..C..C.....GA.AG.....C.T.A.......AG.........C..AG........A..    1462 
KF058902.1   1282      .....T..T...........T..T..C..C.....GA.AG.....C.T.A.......AG.........C..AG........A..    1365 
KF058901.1   1291      .....T..T...........T..T..C..C.....GA.AG.....C.T.A.......AG.........C..AG........A..    1374 
KF058900.1   1291      .....T..T...........T..T..C..C.....GA.AG.....C.T.A.......AG.........C..AG........A..    1374 
AY820253.1   1379      .....T..T...........T..T..C..C.....GA.AG.....C.T.A.......AG.........C..AG........A..    1462 
CP031779.1   44156     ....................T.....T..C.....TA.AG.A...C.C.A......CAGT..G........AA....C...A..    44073 
MH607131.1   16        ....................T.....T..C.....TA.AG.A...C.C.A......CAGT..G........AA....C...A..    99 
CP031537.1   1600511   ....................T.....T..C.....TA.AG.A...C.C.A......CAGT..G........AA....C...A..    1600428 
LC414617.1   94        ....................T.....T..C.....TA.AG.A...C.C.A......CAGT..G........AA....C...A..    177 
CP022905.1   39767     ....................T.....T..C.....TA.AG.A...C.C.A......CAGT..G........AA....C...A..    39684 
CP022908.1   39695     ....................T.....T..C.....TA.AG.A...C.C.A......CAGT..G........AA....C...A..    39612 
CP022906.1   39695     ....................T.....T..C.....TA.AG.A...C.C.A......CAGT..G........AA....C...A..    39612 
CP022904.1   39767     ....................T.....T..C.....TA.AG.A...C.C.A......CAGT..G........AA....C...A..    39684 
CP022903.1   39767     ....................T.....T..C.....TA.AG.A...C.C.A......CAGT..G........AA....C...A..    39684 
CP022902.1   39695     ....................T.....T..C.....TA.AG.A...C.C.A......CAGT..G........AA....C...A..    39612 
CP022894.1   39767     ....................T.....T..C.....TA.AG.A...C.C.A......CAGT..G........AA....C...A..    39684 
CP022893.1   39767     ....................T.....T..C.....TA.AG.A...C.C.A......CAGT..G........AA....C...A..    39684 
CP022582.1   40554     ....................T.....T..C.....TA.AG.A...C.C.A......CAGT..G........AA....C...A..    40637 
CP031130.1   43507     ....................T.....T..C.....TA.AG.A...C.C.A......CAGT..G........AA....C...A..    43424 




LT992477.1   1663985   ....................T.....T..C.....TA.AG.A...C.C.A......CAGT..G........AA....C...A..    1664068 
LT992476.1   177021    ....................T.....T..C.....TA.AG.A...C.C.A......CAGT..G........AA....C...A..    177104 
LT992475.1   2424158   ....................T.....T..C.....TA.AG.A...C.C.A......CAGT..G........AA....C...A..    2424241 
LT992474.1   631791    ....................T.....T..C.....TA.AG.A...C.C.A......CAGT..G........AA....C...A..    631708 
LT992473.1   1869713   ....................T.....T..C.....TA.AG.A...C.C.A......CAGT..G........AA....C...A..    1869796 
LT992472.1   984337    ....................T.....T..C.....TA.AG.A...C.C.A......CAGT..G........AA....C...A..    984254 
LT992471.1   90461     ....................T.....T..C.....TA.AG.A...C.C.A......CAGT..G........AA....C...A..    90378 
LT992470.1   1773424   ....................T.....T..C.....TA.AG.A...C.C.A......CAGT..G........AA....C...A..    1773507 
LT992469.1   2250338   ....................T.....T..C.....TA.AG.A...C.C.A......CAGT..G........AA....C...A..    2250421 
LT992468.1   1363090   ....................T.....T..C.....TA.AG.A...C.C.A......CAGT..G........AA....C...A..    1363007 
LT992467.1   1425442   ....................T.....T..C.....TA.AG.A...C.C.A......CAGT..G........AA....C...A..    1425359 
LT992466.1   228143    ....................T.....T..C.....TA.AG.A...C.C.A......CAGT..G........AA....C...A..    228226 
LT992465.1   1691001   ....................T.....T..C.....TA.AG.A...C.C.A......CAGT..G........AA....C...A..    1691084 
LT992464.1   2639316   ....................T.....T..C.....TA.AG.A...C.C.A......CAGT..G........AA....C...A..    2639399 
LT992463.1   231906    ....................T.....T..C.....TA.AG.A...C.C.A......CAGT..G........AA....C...A..    231823 
LT992462.1   2613893   ....................T.....T..C.....TA.AG.A...C.C.A......CAGT..G........AA....C...A..    2613810 
LT992461.1   999040    ....................T.....T..C.....TA.AG.A...C.C.A......CAGT..G........AA....C...A..    998957 
LT992460.1   924508    ....................T.....T..C.....TA.AG.A...C.C.A......CAGT..G........AA....C...A..    924591 
LT992458.1   565206    ....................T.....T..C.....TA.AG.A...C.C.A......CAGT..G........AA....C...A..    565289 
LT992456.1   1273780   ....................T.....T..C.....TA.AG.A...C.C.A......CAGT..G........AA....C...A..    1273863 
CP030326.1   38816     ....................T.....T..C.....TA.AG.A...C.C.A......CAGT..G........AA....C...A..    38733 
MH188482.1   16131     ....................T.....T..C.....TA.AG.A...C.C.A......CAGT..G........AA....C...A..    16048 
MH188467.1   9845      ....................T.....T..C.....TA.AG.A...C.C.A......CAGT..G........AA....C...A..    9762 
CP030323.1   454886    ....................T.....T..C.....TA.AG.A...C.C.A......CAGT..G........AA....C...A..    454969 
CP029685.1   61204     ....................T.....T..C.....TA.AG.A...C.C.A......CAGT..G........AA....C...A..    61287 
CP027788.1   77623     ....................T.....T..C.....TA.AG.A...C.C.A......CAGT..G........AA....C...A..    77540 
LS483319.1   39840     ....................T.....T..C.....TA.AG.A...C.C.A......CAGT..G........AA....C...A..    39757 
LS483316.1   41880     ....................T.....T..C.....TA.AG.A...C.C.A......CAGT..G........AA....C...A..    41797 
LS483309.1   86514     ....................T.....T..C.....TA.AG.A...C.C.A......CAGT..G........AA....C...A..    86431 
LS483301.1   38803     ....................T.....T..C.....TA.AG.A...C.C.A......CAGT..G........AA....C...A..    38720 
LS483484.1   45041     ....................T.....T..C.....TA.AG.A...C.C.A......CAGT..G........AA....C...A..    44958 
CP029673.1   44162     ....................T.....T..C.....TA.AG.A...C.C.A......CAGT..G........AA....C...A..    44079 
CP029664.1   2631455   ....................T.....T..C.....TA.AG.A...C.C.A......CAGT..G........AA....C...A..    2631372 
CP029663.1   44152     ....................T.....T..C.....TA.AG.A...C.C.A......CAGT..G........AA....C...A..    44069 
CP029657.1   44162     ....................T.....T..C.....TA.AG.A...C.C.A......CAGT..G........AA....C...A..    44079 
CP021171.1   41533     ....................T.....T..C.....TA.AG.A...C.C.A......CAGT..G........AA....C...A..    41450 
CP021141.1   40381     ....................T.....T..C.....TA.AG.A...C.C.A......CAGT..G........AA....C...A..    40298 
CP029680.1   2500817   ....................T.....T..C.....TA.AG.A...C.C.A......CAGT..G........AA....C...A..    2500900 
CP029681.1   2374859   ....................T.....T..C.....TA.AG.A...C.C.A......CAGT..G........AA....C...A..    2374942 
CP029655.1   519320    ....................T.....T..C.....TA.AG.A...C.C.A......CAGT..G........AA....C...A..    519403 
CP029658.1   94470     ....................T.....T..C.....TA.AG.A...C.C.A......CAGT..G........AA....C...A..    94553 
CP029678.1   39228     ....................T.....T..C.....TA.AG.A...C.C.A......CAGT..G........AA....C...A..    39145 
CP029649.1   1748789   ....................T.....T..C.....TA.AG.A...C.C.A......CAGT..G........AA....C...A..    1748872 
CP029675.1   45120     ....................T.....T..C.....TA.AG.A...C.C.A......CAGT..G........AA....C...A..    45037 
CP029667.1   2797945   ....................T.....T..C.....TA.AG.A...C.C.A......CAGT..G........AA....C...A..    2798028 
CP029669.1   2206157   ....................T.....T..C.....TA.AG.A...C.C.A......CAGT..G........AA....C...A..    2206240 
CP029653.1   47550     ....................T.....T..C.....TA.AG.A...C.C.A......CAGT..G........AA....C...A..    47467 
CP029652.1   1638880   ....................T.....T..C.....TA.AG.A...C.C.A......CAGT..G........AA....C...A..    1638963 
CP015447.2   77445     ....................T.....T..C.....TA.AG.A...C.C.A......CAGT..G........AA....C...A..    77362 
CP029172.1   47687     ....................T.....T..C.....TA.AG.A...C.C.A......CAGT..G........AA....C...A..    47604 




MF185206.1   3669      ....................T.....T..C.....TA.AG.A...C.C.A......CAGT..G........AA....C...A..    3586 
CP029087.1   44162     ....................T.....T..C.....TA.AG.A...C.C.A......CAGT..G........AA....C...A..    44079 
CP029086.1   1376537   ....................T.....T..C.....TA.AG.A...C.C.A......CAGT..G........AA....C...A..    1376454 
CP029084.1   735457    ....................T.....T..C.....TA.AG.A...C.C.A......CAGT..G........AA....C...A..    735374 
CP029082.1   844858    ....................T.....T..C.....TA.AG.A...C.C.A......CAGT..G........AA....C...A..    844941 
CP029080.1   504512    ....................T.....T..C.....TA.AG.A...C.C.A......CAGT..G........AA....C...A..    504429 
CP029032.1   39765     ....................T.....T..C.....TA.AG.A...C.C.A......CAGT..G........AA....C...A..    39682 
CP029030.1   39765     ....................T.....T..C.....TA.AG.A...C.C.A......CAGT..G........AA....C...A..    39682 
CP029031.1   39765     ....................T.....T..C.....TA.AG.A...C.C.A......CAGT..G........AA....C...A..    39682 
CP020544.1   44801     ....................T.....T..C.....TA.AG.A...C.C.A......CAGT..G........AA....C...A..    44718 
CP021105.1   41591     ....................T.....T..C.....TA.AG.A...C.C.A......CAGT..G........AA....C...A..    41508 
CP020553.1   47454     ....................T.....T..C.....TA.AG.A...C.C.A......CAGT..G........AA....C...A..    47371 
Note: All accession listed are mecC genes. All accessions after the underlined accession 





APPENDIX F: Novel Real-Time PCR nuc Primer/Probe Sequence Alignment for 





Query       1        
ATTTCGCTACTAGTTGTTTAGTGTTAACTTTAGTTGTAGTTTCAAGTCTAAGTAGCTCAGCAAATGCATCACAAACAGATAATGGCGTAAATAGAAGTGGTTCTGAAGATCCAACAGTATAT
AGTG  126 
CP031661.1  813802   ..............................................................................................................................  813927 
CP031670.1  831670   ..............................................................................................................................  831795 
CP031664.1  813802   ..............................................................................................................................  813927 
CP031673.1  2089402  ..............................................................................................................................  2089277 
CP031667.1  831670   ..............................................................................................................................  831795 
CP031537.1  2435625  ..............................................................................................................................  2435750 
CP022910.1  813119   ..............................................................................................................................  813244 
CP022908.1  854898   ..............................................................................................................................  855023 
CP022906.1  854901   ..............................................................................................................................  855026 
CP022902.1  854897   ..............................................................................................................................  855022 
CP022892.1  817272   ..............................................................................................................................  817397 
CP029685.1  978832   ..............................................................................................................................  978957 
CP027788.1  938327   ..............................................................................................................................  938452 
LS483319.1  852640   ..............................................................................................................................  852765 
LS483316.1  837535   ..............................................................................................................................  837660 
LS483309.1  926632   ..............................................................................................................................  926757 
LS483301.1  874700   ..............................................................................................................................  874825 
LS483365.1  808776   ..............................................................................................................................  808901 
LS483350.1  834943   ..............................................................................................................................  835068 
CP029664.1  1819486  ..............................................................................................................................  1819361 
CP029678.1  884151   ..............................................................................................................................  884276 
CP029667.1  1952260  ..............................................................................................................................  1952135 
CP029669.1  1318637  ..............................................................................................................................  1318512 
CP015447.2  896144   ..............................................................................................................................  896269 
CP029166.1  919631   ..............................................................................................................................  919756 
CP029032.1  866327   ..............................................................................................................................  866452 
CP029030.1  866327   ..............................................................................................................................  866452 
CP029031.1  866327   ..............................................................................................................................  866452 
CP027101.1  1384945  ..............................................................................................................................  1384820 
CP027476.1  866322   ..............................................................................................................................  866447 
CP012119.2  2906380  ..............................................................................................................................  2906505 
CP026962.1  950714   ..............................................................................................................................  950839 
CP026961.1  1690714  ..............................................................................................................................  1690839 
CP026960.1  186985   ..............................................................................................................................  187110 
CP016858.2  500327   ..............................................................................................................................  500202 
CP016855.2  1189831  ..............................................................................................................................  1189706 
CP007539.3  1496696  ..............................................................................................................................  1496571 
CP026080.1  1195457  ..............................................................................................................................  1195332 
CP026077.1  1548751  ..............................................................................................................................  1548876 
CP026076.1  1719528  ..............................................................................................................................  1719653 
CP026072.1  755923   ..............................................................................................................................  755798 
CP026070.1  226957   ..............................................................................................................................  226832 




CP018629.1  1606009  ..............................................................................................................................  1605884 
CP012120.2  486372   ..............................................................................................................................  486247 
CP017094.2  1191716  ..............................................................................................................................  1191591 
CP016861.2  486372   ..............................................................................................................................  486247 
CP025495.1  486372   ..............................................................................................................................  486247 
CP016863.2  2069105  ..............................................................................................................................  2068980 
CP022290.1  815291   ..............................................................................................................................  815416 
CP023560.1  591769   ..............................................................................................................................  591894 
CP023500.1  564559   ..............................................................................................................................  564684 
CP023391.1  856936   ..............................................................................................................................  857061 
CP023390.1  856936   ..............................................................................................................................  857061 
AP014921.1  873798   ..............................................................................................................................  873923 
CP019590.1  886187   ..............................................................................................................................  886312 
CP020619.1  881214   ..............................................................................................................................  881339 
CP014444.1  880279   ..............................................................................................................................  880404 
CP014441.1  875758   ..............................................................................................................................  875883 
CP014438.1  875758   ..............................................................................................................................  875883 
CP014435.1  880038   ..............................................................................................................................  880163 
CP014432.1  875758   ..............................................................................................................................  875883 
CP014429.1  880278   ..............................................................................................................................  880403 
CP014426.1  880278   ..............................................................................................................................  880403 
CP014423.1  880278   ..............................................................................................................................  880403 
CP014420.1  880278   ..............................................................................................................................  880403 
CP014415.1  880279   ..............................................................................................................................  880404 
CP014412.1  880278   ..............................................................................................................................  880403 
CP014409.1  880038   ..............................................................................................................................  880163 
CP014407.1  880280   ..............................................................................................................................  880405 
CP014402.1  880131   ..............................................................................................................................  880256 
CP014397.1  880131   ..............................................................................................................................  880256 
CP014392.1  880131   ..............................................................................................................................  880256 
CP014387.1  880131   ..............................................................................................................................  880256 
CP014384.1  880045   ..............................................................................................................................  880170 
CP014381.1  880038   ..............................................................................................................................  880163 
CP014371.1  880131   ..............................................................................................................................  880256 
CP014368.1  880038   ..............................................................................................................................  880163 
CP014365.1  868983   ..............................................................................................................................  869108 
CP014362.1  868983   ..............................................................................................................................  869108 
CP014376.1  880131   ..............................................................................................................................  880256 
CP009423.1  868803   ..............................................................................................................................  868928 
LT671859.1  839228   ..............................................................................................................................  839353 
CP018205.1  798946   ..............................................................................................................................  799071 
AP017377.1  857787   ..............................................................................................................................  857912 
LT598688.1  856932   ..............................................................................................................................  857057 
CP013959.1  938078   ..............................................................................................................................  938203 
CP013957.1  937408   ..............................................................................................................................  937533 
CP013231.1  2790083  ..............................................................................................................................  2790208 
CP012018.1  907785   ..............................................................................................................................  907910 
CP012015.1  908191   ..............................................................................................................................  908316 
CP012013.1  907519   ..............................................................................................................................  907644 
CP012012.1  909281   ..............................................................................................................................  909406 
CP012011.1  953277   ..............................................................................................................................  953402 
CP007676.1  850613   ..............................................................................................................................  850738 
CP007672.1  862033   ..............................................................................................................................  862158 
CP007657.1  862321   ..............................................................................................................................  862446 
CP007674.1  845630   ..............................................................................................................................  845755 
CP007670.1  875208   ..............................................................................................................................  875333 
CP011526.1  818097   ..............................................................................................................................  818222 
 
Query          1       
ATTTCGCTACTAGTTGTTTAGTGTTAACTTTAGTTGTAGTTTCAAGTCTAAGTAGCTCAGCAAATGCATCACAAACAGATAATGGCGTAAATAGAAGTGGTTCTGAAGATCCAACAGTATAT




NC_017341.1    882081  ..............................................................................................................................  882206 
NC_007795.1    800146  ..............................................................................................................................  800271 
NZ_CP011526.1  818097  ..............................................................................................................................  818222 
NC_002951.2    887822  ..............................................................................................................................  887947 
NZ_CP029031.1  866327  ..............................................................................................................................  866452 
NZ_CP022290.1  815291  ..............................................................................................................................  815416 
NZ_CP010296.1  866327  ..............................................................................................................................  866452 
NZ_CP020020.1  826880  ................C.............................................................................................................  827005 
NZ_CP012409.1  736282   ...............C.................................................................C...........................................  736158 
NC_002758.2    894377   ...............C.................................................................C...........................................  894501 
NC_009487.1    897433   ...............C.................................................................C...........................................  897557 
NC_009632.1    897308   ...............C.................................................................C...........................................  897432 
NZ_CP009361.1  823306   ...............C......................C......................................................................................  823430 
NC_017340.1    853079   ...............C.................................................................C...........................................  853203 
NZ_CP019117.1  866224   ...............C......................C......................................................................................  866348 
NZ_CP010402.1  841618  .....A..........C............................................................................................C................  841743 
NC_017338.1    842204   ...............C..........T......................................................C...........................................  842328 
NC_022226.1    828265   ...............C.................................................................C...................A.......................  828389 
NZ_CP025395.1  870953   ...............C.............................................G...................C...........................................  871077 
NZ_CP022291.1  800682   ...............C.................................................................C.............T.............T...............  800806 
NZ_CP014791.1  803688   ...............C......................C......................................G...C................A.....................C....  803812 





APPENDIX G: Real-Time PCR LOD Results 














D5 1.86E+04 4.27 12 12 100.00   
D6 9.31E+03 3.97 12 12 100.00   
mecC-8 5.96E+03 3.78 12 12 100.00   
D7 4.66E+03 3.67 12 11 91.67 6.34 
D8 2.33E+03 3.37 12 7 58.33 5.2 
mecC-9 5.96E+02 2.78 12 3 25.00 4.33 
Probit value t 95% positive is 6.65     
       
log C95= 3.90      
LOD 
(Copy/ml)= 8.03E+03      
LOD 
(Copy/ul)= 8.03E+00      
LOD 
(Copy/rxn)= 2.01E+02      
       
       














M1 4.98E+03 3.70 11 9 81.82 5.92 
M2 2.49E+03 3.40 11 8 72.73 5.58 
M3 1.24E+03 3.09 11 8 72.73 5.58 
M4 6.22E+02 2.79 11 3 27.27 4.05 
M5 3.11E+02 2.49 11 1 9.09 3.66 
M6 1.55E+02 2.19 12 3 25.00 4.33 
M7 7.77E+01 1.89 12 0 0.00   
M8 3.89E+01 1.59 12 0 0.00   
Probit value t 95% positive is 6.65     
       
log C95= 3.98      
LOD 
(CFU/ml)= 9.53E+03      
LOD 
(CFU/ul)= 9.53E+00      
LOD 
(CFU/rxn)= 2.38E+02      
       
       
       
       
       


















M1 4.98E+03 3.70 11 8 72.73 5.58 
M2 2.49E+03 3.40 11 6 54.55 5.93 
M3 1.24E+03 3.09 11 8 72.73 5.58 
M4 6.22E+02 2.79 11 1 9.09 3.66 
M5 3.11E+02 2.49 11 0 0.00   
M6 1.55E+02 2.19 12 4 33.33 4.56 
M7 7.77E+01 1.89 12 0 0.00   
M8 3.89E+01 1.59 12 0 0.00   
Probit value t 95% positive is 6.65     
       
log C95= 3.52      
LOD 
(CFU/ml)= 3.29E+03      
LOD 
(CFU/ul)= 3.29E+00      
LOD 
(CFU/rxn)= 8.23E+01      
       
       














M1 4.98E+03 3.70 11 9 81.82 5.88 
M2 2.49E+03 3.40 11 5 45.45 4.9 
M3 1.24E+03 3.09 11 6 54.55 5.13 
M4 6.22E+02 2.79 11 3 27.27 4.39 
M5 3.11E+02 2.49 11 2 18.18 4.08 
M6 1.55E+02 2.19 12 0 0.00   
M7 7.77E+01 1.89 12 0 0.00   
M8 3.89E+01 1.59 12 2 16.67 4.05 
Probit value t 95% positive is 6.65     
       
log C95= 4.44      
LOD 
(CFU/ml)= 2.76E+04      
LOD 
(CFU/ul)= 2.76E+01      
LOD 







































































   























APPENDIX H: Real-Time PCR Clinical Validation Results 






Run 1 Run 2 Run 3 Run 4 Run 5 
Mean SD 8/15/2018 1/28/2019 2/6/2019 2/7/2019 2/8/2019 























































































































































































































































































































































































































Run 1 Run 2 Run 3 Run 4 Run 5 
Mean SD 1/27/2019 1/28/2019 2/6/2019 2/7/2019 2/8/2019 










































































































































































































































































































Run 1 Run 2 Run 3 Run 4 Run 5 
Mean SD 1/27/2019 1/28/2019 2/6/2019 2/7/2019 2/8/2019 










































































































































































































































































































Run 1 Run 2 Run 3 Run 4 Run 5 
Mean SD 1/27/2019 1/28/2019 2/6/2019 2/7/2019 2/8/2019 

























































































































































































































































































APPENDIX I: Real-Time PCR Clinical Validation Results 
Sample 
Chromogenic Agar MRSA 
Result 
Qualitative Result mec Ct coa Ct nuc Ct Difference 
S1 NEG True Negative 37.25 NEG NEG 0.00 
S2 NEG True Negative 24.02 NEG NEG 0.00 
S3 NEG True Negative NEG NEG NEG 0.00 
S4 NEG True Negative 21.49 26.71 29.05 7.56 
S5 NEG True Negative NEG NEG NEG 0.00 
S6 NEG True Negative 23.78 NEG NEG 0.00 
S7 NEG True Negative 32.63 NEG NEG 0.00 
S8 NEG True Negative 33.29 NEG NEG 0.00 
S9 NEG True Negative 29.95 NEG NEG 0.00 
S10 NEG True Negative 35.85 NEG NEG 0.00 
S11 NEG False Positive 33.34 32.03 33.25 0.09 
S12 NEG True Negative 27.42 NEG NEG 0.00 
S13 NEG True Negative 26.00 NEG NEG 0.00 
S14 NEG True Negative 28.36 36.91 39.22 9.71 
S15 NEG True Negative 22.52 NEG NEG 0.00 





Chromogenic Agar MRSA 
Result 
Qualitative Result mec Ct coa Ct nuc Ct Difference 
S17 NEG True Negative 22.94 NEG NEG 0.00 
S18 NEG True Negative 33.28 NEG NEG 0.00 
S19 NEG True Negative NEG NEG NEG 0.00 
S20 NEG False Positive 24.46 25.99 25.47 1.27 
S21 NEG True Negative NEG NEG NEG 0.00 
S22 NEG True Negative NEG NEG NEG 0.00 
S23 NEG True Negative 29.50 NEG NEG 0.00 
S24 NEG True Negative 24.79 NEG NEG 0.00 
S25 NEG True Negative NEG NEG NEG 0.00 
S26 NEG True Negative 37.84 33.16 35.88 3.32 
S27 NEG True Negative NEG NEG NEG 0.00 
S28 NEG True Negative 22.59 NEG NEG 0.00 
S29 NEG True Negative 34.34 NEG NEG 0.00 
S31 NEG True Negative NEG NEG NEG 0.00 
S32 NEG True Negative 22.99 NEG NEG 0.00 





Chromogenic Agar MRSA 
Result 
Qualitative Result mec Ct coa Ct nuc Ct Difference 
S34 NEG True Negative 20.67 NEG NEG 0.00 
S35 POS True Positive 28.37 28.56 29.99 0.00 
S36 POS True Positive 28.42 27.58 29.47 0.00 
S37 NEG True Negative NEG NEG NEG 0.00 
S38 NEG True Negative 27.80 NEG NEG 0.00 
S39 NEG True Negative 36.48 NEG 38.19 0.00 
S40 NEG True Negative NEG 25.70 27.32 0.00 
S41 NEG True Negative 34.91 22.88 24.29 11.32 
S42 NEG True Negative 32.70 NEG NEG 0.00 
S43 NEG True Negative 14.97 NEG NEG 0.00 
S44 NEG True Negative 35.39 NEG NEG 0.00 
S45 NEG True Negative 27.83 NEG NEG 0.00 
S46 NEG True Negative 30.60 NEG NEG 0.00 
S47 NEG False Positive 22.31 23.39 23.96 1.37 
S48 NEG True Negative NEG NEG NEG 0.00 





Chromogenic Agar MRSA 
Result 
Qualitative Result mec Ct coa Ct nuc Ct Difference 
S51 NEG True Negative 28.63 NEG 38.82 0.00 
S52 NEG True Negative 30.12 NEG NEG 0.00 
S53 NEG True Negative 27.91 29.68 30.87 2.36 
S54 NEG True Negative NEG NEG NEG 0.00 
S55 NEG True Negative 31.95 NEG NEG 0.00 
S56 NEG True Negative NEG NEG NEG 0.00 
S58 POS True Positive 32.60 31.40 32.98 0.00 
S59 POS True Positive 27.32 26.20 28.90 0.00 
S60 POS True Positive 27.77 26.38 28.95 0.00 
S61 NEG True Negative 22.92 NEG NEG 0.00 
S62 NEG True Negative 30.87 NEG NEG 0.00 
S63 NEG True Negative NEG 37.47 NEG 0.00 
S64 NEG True Negative 24.94 NEG NEG 0.00 
S65 NEG True Negative 35.08 NEG NEG 0.00 
S66 NEG True Negative 26.50 NEG NEG 0.00 





Chromogenic Agar MRSA 
Result 
Qualitative Result mec Ct coa Ct nuc Ct Difference 
S68 NEG True Negative NEG NEG NEG 0.00 
S69 NEG True Negative 27.91 NEG NEG 0.00 
S70 NEG True Negative 27.24 NEG NEG 0.00 
S71 NEG True Negative NEG 28.70 30.00 0.00 
S72 NEG True Negative NEG NEG NEG 0.00 
S73 NEG True Negative 27.42 NEG NEG 0.00 
S74 NEG True Negative 33.25 36.95 NEG 0.00 
S75 NEG True Negative NEG NEG NEG 0.00 
S76 NEG True Negative 31.31 NEG NEG 0.00 
S77 NEG True Negative 34.32 NEG NEG 0.00 
S78 NEG True Negative 29.76 NEG 36.69 0.00 
S79 NEG True Negative 21.21 NEG NEG 0.00 
S80 NEG True Negative 21.17 NEG NEG 0.00 
S81 NEG True Negative NEG 33.71 34.94 0.00 
S82 NEG True Negative 35.90 NEG NEG 0.00 





Chromogenic Agar MRSA 
Result 
Qualitative Result mec Ct coa Ct nuc Ct Difference 
S84 NEG True Negative 35.38 NEG NEG 0.00 
S85 NEG True Negative 17.17 NEG NEG 0.00 
S86 NEG True Negative 32.61 NEG NEG 0.00 
S87 POS True Positive 29.44 28.08 29.68 0.00 
S88 NEG True Negative 32.16 34.46 34.64 2.39 
S89 NEG True Negative 24.22 NEG NEG 0.00 
S90 NEG True Negative NEG NEG NEG 0.00 
S91 NEG True Negative 34.59 NEG 38.20 0.00 
S92 NEG True Negative 35.37 NEG 37.15 0.00 
S93 NEG True Negative 34.60 NEG NEG 0.00 
S94 NEG True Negative 28.60 NEG NEG 0.00 
S95 NEG True Negative 26.89 NEG NEG 0.00 
S96 NEG True Negative 34.07 NEG NEG 0.00 
S97 NEG True Negative 23.21 NEG NEG 0.00 
S98 NEG True Negative 30.89 NEG NEG 0.00 





Chromogenic Agar MRSA 
Result 
Qualitative Result mec Ct coa Ct nuc Ct Difference 
S100 NEG True Negative 24.51 NEG NEG 0.00 
S101 NEG True Negative NEG NEG NEG 0.00 
S102 NEG True Negative NEG NEG NEG 0.00 
S103 NEG True Negative 35.32 NEG NEG 0.00 
S104 NEG True Negative NEG NEG NEG 0.00 
S105 NEG True Negative 26.66 NEG 39.99 0.00 
S106 NEG True Negative 36.14 NEG NEG 0.00 
S107 NEG True Negative 31.61 NEG NEG 0.00 
S108 NEG True Negative NEG NEG NEG 0.00 
S109 NEG True Negative 28.18 NEG NEG 0.00 
S110 NEG True Negative 28.35 34.80 36.63 7.37 
S111 NEG True Negative 33.56 NEG NEG 0.00 
S112 NEG True Negative NEG NEG NEG 0.00 
S113 NEG True Negative 27.21 NEG NEG 0.00 
S114 NEG True Negative 29.93 NEG NEG 0.00 
S115 NEG True Negative 30.68 NEG NEG 0.00 
S116 NEG True Negative 35.12 NEG NEG 0.00 
S117 NEG True Negative NEG NEG NEG 0.00 
S118 NEG True Negative NEG 33.52 23.43 0.00 
S119 NEG True Negative 30.95 35.76 36.75 5.31 
S120 NEG True Negative 30.68 34.46 35.31 4.21 
S121 NEG True Negative NEG NEG NEG 0.00 





Chromogenic Agar MRSA 
Result 
Qualitative Result mec Ct coa Ct nuc Ct Difference 
S123 NEG True Negative 29.17 NEG NEG 0.00 
S124 NEG True Negative 29.83 NEG NEG 0.00 
S125 NEG True Negative 30.08 28.68 NEG 0.00 
S126 POS True Positive 29.32 28.13 29.72 0.00 
S127 NEG True Negative NEG NEG NEG 0.00 
S128 NEG True Negative 22.24 NEG NEG 0.00 
S129 NEG True Negative 33.32 32.97 NEG 0.00 
S130 NEG True Negative 24.70 NEG NEG 0.00 
S131 NEG True Negative 29.63 36.78 39.20 8.36 
S132 NEG True Negative 25.93 22.54 23.55 2.88 
S133 NEG True Negative NEG 36.48 38.30 0.00 
S134 NEG True Negative 31.76 NEG 38.83 0.00 
S135 NEG True Negative 36.61 NEG NEG 0.00 
S136 NEG True Negative 20.54 NEG NEG 0.00 
S137 NEG True Negative 21.84 NEG NEG 0.00 
S138 NEG True Negative 26.93 29.66 31.26 3.54 
S139 NEG True Negative 34.24 NEG NEG 0.00 
S140 NEG True Negative 35.52 NEG NEG 0.00 
S141 NEG True Negative 32.66 NEG NEG 0.00 
S142 NEG True Negative NEG NEG NEG 0.00 
S143 NEG True Negative 31.24 NEG NEG 0.00 
S144 NEG True Negative 26.15 NEG NEG 0.00 
S145 NEG True Negative 36.94 NEG NEG 0.00 
S146 NEG True Negative 32.60 NEG 38.69 0.00 
S147 NEG True Negative 32.33 NEG NEG 0.00 
S148 NEG True Negative 31.44 NEG NEG 0.00 





Chromogenic Agar MRSA 
Result 
Qualitative Result mec Ct coa Ct nuc Ct Difference 
S150 NEG True Negative 28.10 NEG NEG 0.00 
S151 NEG True Negative 21.44 NEG NEG 0.00 
S152 NEG True Negative 21.74 NEG NEG 0.00 
S153 NEG True Negative 25.15 26.96 28.15 2.40 
S154 NEG True Negative 25.41 NEG NEG 0.00 
S156 NEG True Negative 28.44 NEG NEG 0.00 
S157 NEG True Negative NEG 26.48 28.41 0.00 
S158 NEG True Negative NEG NEG NEG 0.00 
S159 NEG True Negative 21.54 NEG 33.79 0.00 
S160 NEG True Negative 30.05 32.18 33.86 2.97 
S161 NEG False Positive 31.39 30.06 31.54 0.58 
S162 NEG True Negative 33.71 NEG NEG 0.00 
S163 NEG True Negative 33.90 NEG NEG 0.00 
S164 NEG True Negative 35.27 NEG NEG 0.00 
S165 NEG True Negative 37.25 NEG NEG 0.00 
S166 NEG True Negative 25.16 NEG NEG 0.00 
S167 POS False Negative 18.81 NEG 37.55 18.74 
S168 NEG False Positive 24.74 26.10 26.96 1.79 
S169 NEG True Negative 20.96 NEG NEG 0.00 
S170 NEG True Negative 29.15 NEG NEG 0.00 
S171 NEG True Negative NEG NEG NEG 0.00 
S172 POS True Positive 30.85 30.43 30.00 0.63 
S173 POS True Positive 30.83 31.32 30.64 0.15 
S174 POS True Positive 24.65 25.08 24.44 0.11 
S175 POS True Positive 26.31 26.68 26.13 0.10 
S176 POS True Positive 28.41 28.43 27.76 0.31 





Chromogenic Agar MRSA 
Result 
Qualitative Result mec Ct coa Ct nuc Ct Difference 
S178 POS False Negative 29.07 34.51 32.15 4.26 
S179 POS False Negative 21.19 30.53 33.11 10.63 
S180 POS True Positive 19.19 19.69 20.26 0.79 
S181 POS True Positive 28.63 28.92 30.06 0.86 
S182 POS True Positive 16.60 17.20 15.98 0.01 
S183 POS True Positive 21.50 21.67 20.19 0.57 
S184 POS True Positive 26.33 32.07 31.78 5.60 
S185 POS False Negative 25.59 33.69 33.15 7.83 
S186 POS True Positive 26.03 24.80 26.25 0.50 
S187 POS True Positive 22.78 28.45 27.61 5.25 
S188 POS True Positive 23.24 23.80 22.62 0.03 
S189 POS True Positive 26.72 27.08 26.75 0.19 
S190 POS True Negative NEG NEG NEG 0.00 
S191 POS True Positive 29.31 31.56 31.39 2.16 
S192 POS True Positive 24.52 27.33 27.07 2.68 
S193 POS True Positive 30.42 32.33 31.54 1.52 
S194 POS True Positive 29.13 31.29 31.28 2.16 
S195 POS True Positive 25.32 26.18 24.98 0.26 
S196 POS True Positive 29.43 31.78 31.52 2.22 
S197 POS True Positive 23.75 24.19 23.73 0.21 
S198 POS True Positive 26.97 27.70 27.34 0.55 
S199 POS False Negative 27.73 30.64 32.28 3.73 
S200 POS False Negative 30.55 35.03 36.63 5.27 
S201 POS True Positive 22.36 21.95 24.22 0.73 
S202 POS True Positive 33.32 32.62 35.16 0.57 
S203 POS True Positive 23.49 23.37 25.11 0.75 
S204 POS True Positive 25.50 25.26 27.32 0.79 
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